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Information, no matter how beautifully it is packaged or repackaged,
does not equal an idea. Information is nothing more than the raw stuff
that might lead you to something new. Having lots of it doesn’t make
you any cleverer. You can segment it, dimension it or color-code it if the
mood takes you. But until it’s seeded with an idea that leads into action,
it’s just a lump of words and figures.
John Hunt, the art of the idea
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1 Abstract
Recent advances in genome sequencing and annotation have provided
major challenges of assigning functions to the magnitude of predicted
novel proteins. In addition, disorders and pathological conditions need
to be related to the responsible protein misregulations. As the analysis
and characterization of low abundant proteins or protein families from
complex mixtures is still out of reach using standard proteomics methods
like 2D-GE/MS or LC-MS/MS, new techniques to circumvent problems
with proteome complexity are of high value.
In this work these challenges are approached by selectively address-
ing enzyme classes based on their activity or affinity profiles for the cre-
ation of subproteomes. [1] Over the past decade activity-based proteomics
(ABP) has developed into a powerful method for the comparison of dif-
ferent proteome states,
[2]
inhibitor screenings
[3]
and discovery of novel
enzymes.
[4]
Our focus was on matrix metalloproteases (MMPs) and sul-
fatases since the activity of both protein families is post-translationally
regulated in vivo, and changes in their respective activity levels are re-
sponsible for several pathological conditions.
[5,6]
Sulfatases cleave a wide variety of sulfate esters with substrate speci-
ficities ranging from sulfated lipids over sulfated steroids to complex sul- Sulfatases
fated proteoglycans. Their physiological involvement in processes like
hormone-dependent cancer, cell signaling and pathogen infection has on-
ly recently been revealed.
[7]
Probes with two different mechanism-based
21
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targeting groups were synthesized, biochemically evaluated and applied
to address this enzyme class with emerging impact.
Figure 1.1: Structures of QM
precursor probe 1 and cyclic sulf-
amate 2.
The first activity-based inhibitor we assessed was the
previously reported quinone methide (QM) precursor
1.
[8,9]
Upon sulfate cleavage by a sulfatase, fluoride is
eliminated and a quinone methide species generated.
This electrophilic intermediate is then supposedly at-
tacked by a nucleophile of the sulfatase active site to
induce inactivation and labeling. 19F-NMR and inhibition studies as well
as labeling experiments with human and bacterial sulfatases were con-
ducted. All studies demonstrated a high turnover rate of QM precursor
probes in combination with unspecifically labeled background proteins.
To overcome these problems, cyclic sulfamates (CySAs) 2 were inves-
tigated for their inhibitory potential against a panel of human and bacte-
rial sulfatases. The CySA binding mechanism was partially elucidated by
chemoselective labeling of the sulfatase active site residue formylglycine
(FGly). Additionally CySA probes were able to label sulfatases with im-
proved selectivity compared to quinone methide type probes. A novel
bioorthogonal in situ labeling procedure utilizing copper catalyzed azide-
alkyne cycloaddition (CuAAC) was implemented for this probe class.
Human MMPs play a role in cancer-related processes like metastasis
and angiogenesis as well as in normal and pathological tissue remodelingMatrix metallo-
proteases (e.g. wound healing, placenta reduction after child birth or rheumatoid
arthritis).
[10]
So far MMPs have mostly been studied using traditional bio-
chemical methods such as zymography for visualization of activity states
in physiological fluids like blood, plasma or synovia.
[11]
In contrast to the
magnitude of zymography-based studies, there are only few examples
for affinity-based photoinduced covalent MMP labeling,
[12–17]
the charac-
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terization of reversibly binding MMP probes
[18,19]
and inhibitor affinity
chromatography of MMPs from synovia.
[20]
The concept of photoreactive affinity-based probes was applied to the
selective labeling of Arabidopsis thaliana MMPs (At-MMPs). Of the five At-
MMPs which were discovered by homology searches using human MMP-
7
[21]
four At-MMPs were transiently expressed via Agrobacterium tumefa-
ciens infiltration of Nicotiana benthamiana leaves. Infected leaves showed a
phenotype which was a first strong indicator for metalloprotease activity.
Protein expression was reviewed and optimized by western blotting of
the leaf extracts using a hemagglutinin (HA) tag.
Figure 1.2: At-MMP targeting probe 3. Marimastat-based
affinity probe, photoreactive group, biotin.
The well-known hydroxamic
acid marimastat
[22]
was cho-
sen for this affinity-based
approach since the high
homology between human
MMP-7 and the At-MMPs
might render them suscep-
tible to this inhibitor. Mari-
mastat affinity labeling of
At-MMPs was realized by
application of a tool developed in cooperation with caprotec bioanalytics
GmbH, Berlin. They attached a marimastat-based affinity probe synthe-
sized in our laboratory
[19,23,24]
to a perfluorinated aryl azide photoreac-
tive group and biotin as reporter group. Probe 3 binds to MMPs based
on the reversible marimastat moiety, and upon UV-irradiation the pho-
toreactive group establishes a covalent bond to the captured protein. The
protein-probe complex can then be extracted by streptavidin pull-down.
Probe 3 was validated by IC50-value determination for the inhibition of
human MMP-2 following a previously established protocol
[19,23]
as well
23
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as labeling of human MMP-9 before applying it to affinity-based label-
ing of At-MMPs. A specific and covalent interaction between the human
MMP inhibitor marimastat and several At-MMPs as well as an endoge-
nous MMP from Nicotiana benthamiana was demonstrated by LC-MS/MS
analyses as well as streptavidin blotting.
24
2 Introduction to Activity- and
Affinity-Based Proteomics
Proteomics comprises the analysis of the whole complement of proteins,
and this includes the elucidation of various protein characteristics apart
from abundance. Structure, interactions, post-translational modifications,
localization and enzymatic activity are all decisive features for protein
function. Assessing this information at once in a given proteome is out of
reach even with the latest techniques at hand. Moreover, proteome states
are time- and condition-dependent and neither accurately defined nor
static.
[25]
Apart from conventional 2D-GE followed by fingerprint ana-
lysis for identification of the separated proteins, several high-throughput
techniques for proteome characterization have been developed including
LC-MS/MS strategies
[26]
and protein microarrays.
[27]
Yet, all of them still
fail to assess in vivo activity of proteins which is arguably the most im-
portant protein feature since it is directly responsible for physiological
or pathological conditions observed. There has been and still is a need Why do we
need ABP?for new tools to measure and detect specific activities within whole pro-
teomes. One approach in chemical proteomics is to target enzymes with
active site-directed activity- or affinity-based probes which is commonly
referred to in the literature as activity-based proteomics (ABP).
[28]
ABP displays the most powerful technique up to date for the selec-
tive analysis of active enzymes. Figure 2.1 schematically shows the two
main workflows. Synthetic small molecule probes containing a target-
25
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ing group and a tag connected by a linker are utilized to covalently label
active sites of enzymes in a protein sample.
Figure 2.1: Schematic representation of
the main ABP procedures. a) Biotiny-
lated proteins are separated via streptavi-
din pull-down. After washing the bound
proteins are trypsinated and identified by
LC-MS/MS. b) Fluorescence dye-labeled
proteins are visualized in-gel, trypsinated
and identified in MS fingerprint analysis.
Biotinylated probes are used to first enrich
labeled proteins on avidin or streptavidin
beads and thereby separate them from the
non-labeled background. Bound proteins are
trypsinated directly on beads and identified
in gel-free LC-MS/MS analysis. Fluorescent
probes are used for gel-based approaches with
protein separation via 1D- or 2D-GE. Label-
ing events are visualized in-gel with a fluores-
cence scanner allowing the subsequent finger-
print analysis of labeled proteins for identifi-
cation purposes.
Most probes bind a wide variety of en-
zymes of the same family or with similar cat-
alytic properties. Thereby, a whole group
of proteins is rendered susceptible to down-
stream analysis in one experiment.
[29]
The ma-
jority of activity-based studies aim at the un-
derstanding of enzyme involvement in spe-
cific processes
[2]
thus improving the knowl-
edge on the relationship between activity and
function of many enzyme classes.
[30]
Another important application ofABP
applications ABP is inhibitor screening using a sophisticated probe in combination
with inhibitors displaying uncharacterized inhibition profiles. A complex
protein sample is pre-incubated with the inhibitor before labeling with
the probe, and from the binding competition between them, new protein
targets of unknown inhibitors can be assigned.
[31]
A multitude of reviews
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has been published on ABP summarizing biochemical results and appli-
cations comprehensively.
[32–36]
This introduction gives a condensed sum-
mary of the growing field and exemplarily shows synthetic approaches
and biochemical applications possible so far pointing at drawbacks and
limitations.
2.1 Probe Design – the Crucial Step
Synthetic probes are the basis of each activity- or affinity-based study.
They consist of a targeting group responsible for binding to the protein
of interest, a linker and a reporter tag which is usually biotin or a fluo-
rescence dye. Sensible probe design is the prerequisite for the success of
subsequent biochemical applications. All probe moieties have to be ad-
justed to the scope of each individual study since shortcomings in design
are costly if the synthetic strategy has to be altered and probe synthesis
repeated.
2.1.1 Targeting Groups
The key feature of all probes is the targeting group since it is decisive
for the proteins which are actually labeled. There are examples for irre-
versible as well as reversible inhibitors in ABP approaches. Irreversible
inhibitors are incorporated into activity-based probes which necessitate
probe conversion by the target enzyme for labeling.
Activity-based probes as displayed in Figure 2.2 are usually attacked
by the enzyme to directly create a covalent adduct (mechanism-based in-
hibitors, 4–8). Alternatively, a reactive derivative of the probe is created
in the course of the enzyme reaction that should immediately bind and
inactivate the enzyme (suicide inhibitors, 1).
27
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Figure 2.2: Structures of examplary activity-based
probes: fluorophosphonate 4,
[28]
alkylphospho-
nate 5,
[37]
epoxysuccinyl derivative 6,
[38]
β-lactam
7,
[39]
monofluoromethylphenyl sulfate 1,
[8,40]
α-
chloroacetamide 8.
[41]
There are two main strategies for the
design of activity-based probes: di-
rected (1, 4–7) and non-directed (8).
Activity-based probes react with an
enzyme class mostly based on active
site nucleophilicity, thus fine-tuning of
probe specificity often involves incor-
poration of amino acids or amino acid
derivatives to mimic the enzyme sub-
strates.
Fluorophosphonates 4 constitute one
of the first probe classes extensively used for activity-based proteomics
[28]
and have yielded a lot of biological information so far. These probesDirected
display a high degree of promiscuity by generally phosphorylating ac-
tive site serine residues of many serine hydrolases. This has led to the
assignment of numerous previously uncharacterized proteins as serine
hydrolases.
[42]
Fluorophosphonates 4 have also been applied in high-
throughput screenings of compound libraries to identify potent specific
inhibitors for single enzymes with unknown substrates. A broad-range
binding probe for the whole class of serine hydrolases allowed the direct
identification of off-target hits bound by the tested inhibitors.
[43]
Peptidic
aryl- and alkylphosphonates like 5 have been developed to enable a more
selective labeling of serine hydrolases. The incorporated amino acids im-
itate substrates; probe 5 is applied for postproline protease labeling.
[37]
Epoxysuccinyl derivatives 6 are attacked by catalytic cysteine residues
of the papain class of cysteine proteases thereby labeling a range of diffe-
rent enzymes.
[38]
The employment of more selective epoxysuccinyl probes
has been described, e.g. the selective labeling of Cathepsin B which was
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achieved by incorporation of a substrate-like dipeptide instead of the
ethyl ester in 6.
[44]
Most ABP studies so far concentrate on enzymes which have previ-
ously been suggested as biomarkers for cancer. Recently, novel targets
for ABP studies are emerging, among them bacterial enzymes involved
in cell wall biosynthesis associated with antibiotics resistance. Various
bacterial lysates were profiled successfully with β-lactams 7,
[39,45]
and β-
lactone libraries.
[46]
The probes and their bacterial targets will now be
further evaluated e.g. by inhibitor screenings.
Figure 2.3: Binding mechanism of sulfatase
probe 1, a quinone methide precursor.
Suicide inhibitor 1 is turned over by a sul-
fatase. These compounds depend on the
cleavage of their respective substrate moi-
eties (sulfate in Figure 2.3), whereupon fluo-
ride elimination generates the QM. The elec-
trophilic carbon atom generated by sulfate
cleavage should be attacked by a nucleophile
of the sulfatase, supposedly, an active site
residue. A diverse group of enzymes has
been addressed by quinone or quinolimine methides but except for one
example,
[47]
all studies still fail to prove the practicability of these com-
pounds in complex samples, the target of all application-oriented ABP
studies. Only purified enzymes were tested, and any unspecific labeling
in more elaborate experiments was ignored.
[8,48–57]
Two of these studies
hint towards the problem of unspecific binding. However, there are no
follow-up publications affording details on these initial results.
[53,54]
Pos-
sibly, the generated quinone methide is stable enough to diffuse out of the
sulfatase active site. As a result, it labels surrounding molecules leading
to false positive hits which question the applicability of QM precursors
for ABP approaches in general.
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The lack of specific covalent inhibitors for many enzyme classes or pro-Non-directed
tein families has led to the development of non-directed probe libraries
containing general electrophiles like α-chloroacetamides or sulfonate es-
ters to screen for novel targets which were not addressed by ABP before.
One successful example for the application of a non-directed probe stra-
tegy is the α-chloroacetamide 8. This probe was identified from a library
of α-chloroacetamides to selectively target the nitrilase Upβ because of
structural similarities to its natural substrate N-carbamoyl β-alanine. [41]
Such examples prove the utility of non-directed probes for the assignment
of substrates to novel enzymes.
Another important innovation for approaching a larger variety of en-
zymes using ABP workflows was made with the integration of photore-
active groups into probe design.
[58]
Many enzyme classes which wereAffinity-based
targeting
groups
neither attacked by directed nor non-directed activity-based probes can
be captured with affinity-based probes that contain a reversible inhibitor
in combination with a photoreactive group (Figure 2.4).
Figure 2.4: Structures of affinity-based probes: mari-
mastat derivative 3,
[59]
(3S,4S)-statine probe 9,
[60]
H9-containing probe 10.
[61]
Affinity functions, pho-
toreactive groups.
Publications on affinity-based pro-
bes are mainly concerned with me-
talloprotease (MP) labeling since
there are no mechanism-based in-
hibitors for this group of enzymes
which do not possess active site nu-
cleophilic residues. Instead, MP
substrates are cleaved by an ac-
tivated water molecule which is
complexed through a zinc ion and
an aspartate residue.
[62]
Probe 3
was developed as a commercial
tool for the functional characteriza-
30
2.1 Probe Design – the Crucial Step
tion of MMPs in the course of this thesis.
[59]
It contains the well-known
broad range MMP inhibitor marimastat and a photoreactive group to co-
valently label bound proteins upon UV-irradiation. Other hydroxamate
probe libraries with benzophenone as the photoreactive group have been
used for a case study about ranking human MMP-13 PubChem screening
hits.
[63]
Various enzyme classes were targeted by affinity-based probes with di-
verse photoreactive groups as shown exemplarily by probe 9 binding as-
partic proteases
[60]
and probe 10 addressing kinases.
[61]
The advantages
and drawbacks of the different photoreactive groups employed have been
extensively discussed in literature.
[64]
This particular strategy renders
affinity-based probes susceptible to activity-based methods by covalent
bond formation and will eventually lead to an amplification of ABP re-
sults.
2.1.2 Tagging Strategies
Depending on the application of ABP probes, different tags
[65]
can be
attached during synthesis. The smallest labels available for probe syn-
thesis are radiolabels. Radioactive isotopes like 125I can be introduced
into phenyl rings without heavily altering probe structure. Even if an 125I
aromatic system has to be integrated into the probe for the purpose of
radio-labeling, it creates a relatively small change compared to the ad-
dition of biotin or a fluorophore. Unfortunately, radio-isotopes are not
robust enough for long-term storage, so the label has to be attached to the
targeting group immediately prior to probe application.
[66]
Another possibility for gel-free ABP experimental setups is the addi-
tion of stable isotopes, which have been used in quantitative proteomics Stable
isotopesfor years.
[67]
Although there are only few studies with probes that incor-
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porate stable isotopes, this is a powerful method for the relative quanti-
tation of labeled enzymes originating from different proteomes.
[68]
The reduction of sample complexity by ABP approaches is tightly con-
nected to one of the most prominent tags applied in biochemical research:
biotin. The strong binding to avidin and streptavidin allowed its applica-Biotin
tion in affinity blotting and pull-down using avidin or streptavidin coated
beads.
[2,8,28,29,38–40,42–46,50,51,55,56,58,59,68]
The captured proteins can subse-
quently be analyzed (Figure 2.1). Since endogenously biotinylated pro-
teins cause a background of detected but non-labeled proteins, alternative
unambiguous reporter tags were applied early on in ABP evolution.
In comparison to biotin, fluorophores offer the advantage of imme-
diate in-gel visualization (Figure 2.1) and the feasibility of fluorescence
microscopy. No inherently fluorescent proteins (apart from e.g. GFP) in-
terfere with the read-out which is the reason for the high sensitivity of this
method. A multitude of fluorophores with different physico-chemical
properties are commercially available as reactive esters which facilitatesFluorophores
probe synthesis. The first fluorophores applied in ABP were rhodamine
and fluorescein dyes.
[28,69]
Their disadvantage of photobleaching has led
to the incorporation of dipyrromethene boron difluoride (BODIPY) and
cyanine (Cy) dyes that display higher fluorescence quantum yields, an
improved pH tolerance, excellent photostability and higher absorption
coefficients which makes them more suitable for microscopy. They are
able to penetrate cell membranes, and this allows for in vivo labeling. [70]
Novel minimally invasive diagnostic imaging methods might be deve-
loped in the future as has been shown for near-infrared fluorescent in
vivo labeling of tumors by application of activity-based probes in living
mice.
[71,72]
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2.1.3 Probe Assembly and Linker Design
A considerable amount of probes synthesized so far relies on peptide
chemistry for the coupling of their three components targeting group,
linker and tag. Additionally, many inhibitory groups are peptide deriva-
tives which narrows the range of chemical reactions needed for probe
assembly down and allows the application of established conditions and
reagents. Some probes were even synthesized using solid phase peptide
chemistry.
[47]
A recent advance in linker and probe synthesis was made when CuA- CuAAC
AC also known as one of the “click” reactions was first introduced to
ABP.
[73]
This reaction does not only facilitate probe synthesis, moreover, it
improves the practicability of many probes for in vivo labeling. Some tags
(biotin, rhodamine, fluorescein) hinder membrane permeability which
can be overcome by the synthesis of alkyne-modified targeting groups.
The sample is labeled in vivo, homogenized or fixed on a slide for mi-
croscopy, and finally the reporter group is added via CuAAC (Figure 2.5).
Figure 2.5: In vivo labeling using clickable probes. Tissue or cell samples are labeled
with the alkyne-bearing targeting group. The sample is then either a) homogenized,
biotin is added via CuAAC followed by pull-down and protein identification or b) fixed
on a slide for fluorescence microscopy, and a fluorophore azide is attached to visualize
localization of labeled proteins.
Another disadvantage of the biotin tag is solved by incorporation of a Linkers
cleavable site into the linker moiety. The biotin-avidin/streptavidin in-
teraction is too strong to efficiently release captured proteins without ap-
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plication of harsh conditions. Cleavable linkers offer the possibility to
elute proteins via selective mechanisms like photo cleavage,
[74,75]
and to-
bacco etch virus protease cleavage.
[76]
A variant of the cleavable linkers
are degrading linkers which decompose upon substrate-mimic cleavage.
This offers the opportunity to include FRET-pairs into the probe enabling
visualization only upon target protein binding.
[57]
Since this concept also
relies on the generation of QMs its applicability remains to be proven for
complex samples.
The recent years have seen a great methodological advance in activity-
based proteomic research. This technique-oriented field has rather as-
pired to develop new methods to tackle increasingly complex problems
than to actually apply the existing methods to biological systems. Most
break-through studies published in ABP so far depend on the application
of novel chemical strategies for probe synthesis which allow for the im-
plementation of new biochemical procedures (e.g. CuAAC). It remains
unclear whether ABP will be able to meet the challenge of focussing on
the generation of biologically relevant information and not only on im-
proving and developing techniques and methods. After all, many in-
teresting enzyme classes are already addressable by probes but still lack
sufficient functional characterization.
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Sulfatases catalyze the hydrolytic cleavage of sulfate esters and sulfa-
mates with broad substrate specificities across the members of this en-
zyme class. They are structurally and mechanistically highly conserved
and widely distributed among eukaryotes and prokaryotes.
[7]
During the
past 20 years, great advance has been made in their exploration and cha-
racterization.
3.1 Introduction to Sulfatases
All sulfatases feature the same active site residue FGly that is post-trans-
lationally introduced by formylglycine generating enzymes (FGE for eu-
karyotes, AtsB, SUMF1 or similar proteins for prokaryotes) within the
special signature sequence (C/S)TPSR(S/A)(A/S)LLTGR.
[7,77,78]
The hu-
man sulfatases are all processed for the secretory pathway and thus enter The FGly
residuethe endoplasmatic reticulum (ER) during their synthesis. In the course
of this translocation, and before protein folding the FGly residue is gene-
rated by FGE.
[79]
It is generated via oxidation of a cysteine residue for
all eukaryotic enzymes
[80,81]
and of either a serine
[82]
or a cysteine
[83]
residue for the prokaryotic sulfatases. Human sulfatases are glycosylated
and display various localizations along the secretory way: within the ER,
Golgi network, lysosomes and on the cell surface. Prokaryotic sulfatases
are mostly localized in the cytosol or periplasma.
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Figure 3.1: Structure of the highly conserved sulfa-
tase active site.
[7]
There are 17 human, at least eight
other eukaryotic and more than
five prokaryotic sulfatases described
so far.
[9,84]
Three of the human
(ARSA,
[85]
ARSB
[86]
and STS
[87]
) and
one prokaryotic sulfatase from Pseu-
domonas aeruginosa (PARS [88]) have
been structurally characterized by x-
ray crystallography. All four en-
zymes display very similar globular
shapes, except for the unique trans-
membrane domain of STS which con-
sists of two hydrophobic helices protruding into the membrane. The ca-
talytic site is formed by ten amino acids that are highly conserved and
closely involved in a H-bond network which ties the side chains to an
octahedrally coordinated M2+ ion and sulfate (Figure 3.1). Substrate re-
cognition, and consequently, enzyme specificity is most likely due to pro-
tein surfaces other than the active site since most sulfatases readily accept
small aryl sulfate esters as substrates. This hints towards a specific bind-
ing and correct orientation of large substrates by interactions with areas
distant to the catalytic cleft.
[7]
Two mechanisms of sulfate cleavage have been discussed during the
past 15 years. Structural similarities of the first human sulfatase that
was crystallized (ARSB) to alkaline phosphatase inspired the addition-Mechanism of
sulfate
cleavage
hydrolysis (AH) mechanism depicted in Figure 3.2a.
[86]
The structure of
ARSA on the other hand suggested that FGly is only active in its hydrated
form and thus a transesterification-elimination (TE) mechanism was pro-
posed as can be seen in Figure 3.2b.
[85]
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Figure 3.2: Proposed mechanisms for sulfate cleavage. a) AH mechanism: FGly is attacked by an
oxygen atom of the sulfate group. First the alcohol is substituted by water, then sulfate is released
to regenerate the aldehyde. b) TE mechanism: The geminal diol attacks sulfate, and the alcohol is
eliminated to give a sulfate enzyme intermediate. Upon sulfate elimination the diol is regenerated by
water.
.
.
.
.
.
.
.
.
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In case of the TE mechanism, the FGly-hydrate nucleophilically attacks
the sulfur atom of a sulfate, the alcohol is released, and an intermediate
enzyme bound FGly-sulfate ester is formed. The second geminal hydroxy
group is essential for sulfate release to regenerate the aldehyde. This
mechanism is supported by ARSA and B mutants that feature a serine
residue instead of FGly in the active site. The mutants are able to release
the alcohol of a sulfate ester whereas the sulfate remains bound to the
protein.
[89]
This study strongly argues for the TE mechanism and against
the AH mechanism due to the relative unlikeliness of a nucleophilic at-
tack of the serine residue by the sulfate oxygen atom. More proofs for a
TE mechanism include inversion of configuration at the sulfur atom of a
chiral substrate,
[90]
and the high-resolution (1.3 Å) x-ray crystallographic
structure of PARS which clearly shows the FGly-hydrate in close proxim-
ity (2.96 Å) to a sulfate group.
[88]
Today it is generally accepted that the
FGly aldehyde is hydrated to a geminal diol in its active form. However,
it is still under discussion whether the TE mechanism rather follows a SN2
or SN1 pathway. In the majority of studies a dissociative SN1 mechanism
is considered most likely. For bacterial
[91,92]
as well as human
[93]
sulfa-
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tases the pKa, and therefore the leaving group properties of the alcohol
play a decisive role for the enzymatic cleavage of sulfate esters.
STS upregulation was found to be prominent in hormone-dependent
breast cancer of post-menopausal women
[94]
as well as prostate tumors.
[95]
Sulfatase
inhibition Several hormone precursors can be transformed to highly affine estro-
genic or androgenic hormones by STS hence inducing cell proliferation
and growth.
[96]
Figure 3.3: Potent sulfamate inhibitors EMA-
TE and 667COUMATE.
Therefore, significant efforts have been
put forward to develop potent inhibitors
for human steroid sulfatase. The pro-
totypic and potent inhibitor estrone-3-O-
sulfamate (EMATE) was one of the first
irreversible STS inhibitors described.
[97]
Even though it turned out to be highly estrogenic itself and therefore
useless as a therapeutic,
[98]
it started the development of numerous
sulfamate-type compounds including 667COUMATE which underwent
a promising phase I clinical trial.
[99]
Other interesting applications for in-
hibitors arise from the importance of sulfatases in processes like bacterial
pathogenesis,
[100]
and the evasion of plant defense mechanisms against
insects.
[101]
Small aryl sulfamates have been reported to inhibit sulfatases from
various sources. However, their inhibitory mechanism has not been elu-
cidated yet as the dead-end adduct of sulfatase inhibition has never been
identified.
[9,92,102]
Irreversible inhibition of sulfatases was proven as ac-
tivity is not regained even after extensive dialysis. Also, substrate pro-
tection has been observed which is consistent with an inactivation me-
chanism that involves covalent modification of the active site.
[9]
The scis-
sion of the arO-S bond during inhibition was proven by estradiol-3-O-
sulfamate which was [3H]-labeled at the 17-position of the steroid moi-
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ety. Even though irreversible inhibition of the sulfatase was found, the
enzyme was not 3H-labeled.
[96]
The stoichiometry of inhibition was de-
termined for several sulfamates including 667COUMATE to be between
three and six inhibitor molecules per sulfatase before complete inhibi-
tion is attained.
[92]
Encompassing all this information various inhibitory
mechanisms have been proposed as depicted in Figure 3.4.
Figure 3.4: Proposed mechanisms for sulfatase inhibition by sulfamates.
[9,92]
3.1.1 Activity-Based Studies of Sulfatases
Sulfatases are interesting targets for activity-based studies due to two
facts: for some of them the substrates as well as functions are poorly un-
derstood, and lately their involvement in various diseases is unraveling.
Additionally, as accounts for all enzymes, protein abundance does not
reflect biological activity, and sulfatase activity has been found up- and
down-regulated in cancer and inflammation.
[7]
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Quinone methide precursors have been extended to sulfatases
[8,9,103]
prob-
ably in light of precedent with other hydrolytic protein classes, including
phosphatases,
[50]
β-glucosidase,
[51]
proteases,
[53]
neuramidase
[56]
and β-
galactosidase.
[57]
The concept of QM traps is based on the generation
of quinone methide intermediates which feature an electrophilic carbon
atom that can be covalently captured via Michael-addition by a properly
disposed nucleophile. Ideally, an active site residue of the target enzyme
will capture the QM before it can diffuse out of the active site where it
was generated. As shown schematically in Figure 2.3, the QM is masked
as a fluoromethylphenol sulfate substrate surrogate prior to interaction
with the enzyme. After cleavage of sulfate, fluoride is eliminated and the
QM intermediate thereby generated.
In previous work, biochemical studies with PARS indicated that di-
fluoromethylphenyl sulfate (DFPS) inhibitors were acting as competitive
substrates or inhibitors, but not necessarily active-site directed inactiva-
tors as they do not exhibit time- and concentration-dependent inhibi-
tion of sulfatases,
[9]
a hallmark of mechanism-based inhibition.
[104]
In
accordance to that, DFP substrates have demonstrated complicated ki-
netic behavior not following expected first-order kinetics and slow as well
as loose binding in comparison to monofluoromethylphenyl substrates
before.
[105,106]
A biotinylated monofluoromethylphenyl sulfate (MFPS) QM precur-
sor probe which was used for labeling STS did not display convincing
results concerning labeling specificity and mechanism-based inhibition
by MFP QMs.
[8]
The streptavidin-HRP western blot analysis of labeling
clearly visualizes a number of proteins other than STS which were cola-
beled. No inhibition study was conducted, and the only evidence for an
activity-dependent inhibition of STS shows a deviation of 40 % from the
expected value. The most devastating result of this study was only pre-
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sented in the supporting information. In a labeling study without strepta-
vidin bead pull-down it becomes evident that nearly the whole proteome
was labeled by this QM probe.
[8]
However, without further investigation,
it cannot be excluded that the MFPS inhibitor moiety might be useful un-
der optimized conditions or for other members of the sulfatase family.
A different approach was followed in a recently published study to
increase specificity of a QM-based STS-inhibitor. An estrone-type QM
was employed instead of the more general MFPS structure. Notably, the
greater similarity to its natural substrate did not lead to a higher degree of
binding specificity as was inferred from other inhibitors such as EMATE
or 667COUMATE, since multiple QMs had to be generated before STS
was inactivated. Only inhibition studies were presented in this publica-
tion, no labeling results were shown.
[103]
Therefore, a more specific bind-
ing in spite of multiple QM generation per enzyme unit is still possible.
An alternative motif for the development of activity-based sulfatase
probes was presented in the first paper on sulfatase targeting QM pre-
cursors.
[9]
The authors examined the inhibitory characteristics of CySAs
on PARS. They were able to prove it was a mechanism-based covalent in-
hibition which exhibited time- and concentration-dependent properties.
Thus, CySAs are promising candidates for more specific sulfatase probes
since most of the proposed binding mechanisms (depicted in Figure 3.4)
lead to a specifically labeled sulfatase.
3.2 Objectives
ABP tools for the selective detection and isolation of sulfatases within
complex mixtures should be developed in the course of this work. In this
regard, two probe types with different traps were synthesized and bio-
chemically evaluated: QM precursors based on MFPS, and CySA probes.
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A diploma thesis
[107]
conducted in our laboratories provided the fluores-
cein-containing probe 1a depicted in Figure 3.5. In continuation to the
synthesis of 1a, a novel route for the modular synthesis of QM probes but
also ABP probes in general should be explored using CuAAC reactions
for orthogonal probe assembly on solid support.
Figure 3.5: Fluorescein-bearing QM probe 1a.
[107]
In cooperation with Dr. S.R. Hanson (TSRI, La Jolla) alkynylated cyclic
sulfamates and azido-reporter groups were synthesized. These building
blocks should help to extend the range of biochemical experiments feasi-
ble in our lab to in situ and in vivo labeling of proteomes by application of
CuAAC reactions.
On the biochemical side of this project, the inhibition of different sulfa-
tases by QM and CySA probes needed to be evaluated by dose-dependent
sulfatase inhibition assays and various labeling studies to determine and
compare probe properties like inhibition and specificity of QM versus
CySA traps.
3.3 Synthesis of Sulfatase Probes
3.3.1 Quinone Methide Precursors
The synthesis of QM inhibitory fragments based on MFPS included key
steps of installing a TCE protected sulfate before introducing the benzylic
fluoride with DAST. Fluorescent probe 1a was synthesized by a solution-
phase route via a key coupling of the masked inhibitory QM amine with
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fluorescein isothiocyanate.
[107]
In contrast to that, the biotinylated probe
1b was prepared using a modular approach based on peptide coupling
and CuAAC. The inhibitory moieties and the reporter groups can be or-
thogonally attached without protection group modifications.
The synthesis of inhibitor moiety 15 proceeded smoothly except for de-
protection of the hydroxyl groups (step c) in Figure 3.6). Product 13 could
not be extracted from the aqueous phase which then had to be lyophilized
prior to adsorption on celite for chromatographic purification. This led to
a high loss of product in this step.
Figure 3.6: Synthesis of probe precursor 15. a) Ac2O, pyridine, 0 ◦C, 30 min, 86 %; b)
0.8 eq. propargylamine, 1.9 eq. EDC·HCl, 2.9 eq. TEA, DCM, rt, on, 90 %; c) NaOH,
MeOH, 0 ◦C–rt, 3 h, 17 %; d) 3.6 eq. 2,2,2-trichloroethyl chlorosulfate, 1.2 eq. DMAP,
1.4 eq. TEA, DCM, rt, 19 h, 91 %; e) 1.9 eq. DAST, DCM, -20 ◦C–rt, 15 h, 99 %.
.
.
.
.
.
.
.
.
.
.
.
.
. .
To increase QM electrophilicity and reactivity at the position of enzyme
nucleophilic attack, we synthesized a second MFPS 20 according to the re-
action scheme in Figure 3.7. Key step was the deprotection of the sulfate
ester which only proceeded very slowly and needed a large amount of ac-
tivated zinc compared to previous reactions (step d) in Figure 3.9). After
purification by preparative HPLC only 16 % (10 mg) of pure product 20
were obtained. In the course of its NMR-spectroscopic characterization,
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it became evident that 20 is not stable since it decomposed completely
during overnight measurements.
Figure 3.7: Synthesis of probe precursor 20. a) 2.4 eq. Boc2O, Mg(ClO4)2, DCM,
reflux, on, 73 %; b) 1.1 eq. Mg, THF, reflux, 4 h; c) 0.8 eq. ethyl-3,3,3-
trifluoropyruvate, THF, -78 ◦C–rt, on, 66 %; d) TFA, rt, 20 min, quant.; e) 3.3 eq.
2,2,2-trichloroethyl chlorosulfate, 1.1 eq. DMAP, 1.3 eq. TEA, DCM, rt, on, 62 %;
f) 3.3 eq. DAST, DCM, -20 ◦C, 1 h, then rt, on, 89 %; g) 1.5 g activated Zn dust,
MeOH/PBS pH 7.2 = 1:1, rt, 2 d, 16 %.
All attempts to incorporate a trichloroethyl-protected derivative of 20 into
a probe failed since coupling of propargylamine to the carboxylic acid
using EDC/HOBt, PyBOP
[108]
or N,N’-carbonyldiimidazole [109] did not
lead to amide formation even though these conditions had been reported
for very similar molecules.
As a reporter group, we wanted to be able to employ biotin as well
as a fluorophor for the orthogonal probe assembly on resin. To extend
the panel of biochemical applications, we wanted to synthesize a BODI-
PY dye derivatized as a carboxylic acid. Compared to fluorescein-func-
tionalized probes, BODIPY-bearing probes are suitable for fluorescence
microscopy. This specific BODIPY dye was selected due to its similar
spectroscopic characteristics with respect to fluorescein.
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Figure 3.8: Synthesis of BODIPY dye 21. a)
1.3 eq. BF3·OEt2, DCM, reflux, 5 h; b) 6.7 eq.
BF3·OEt2, 5 eq. TEA, rt, on.
Despite following a published proce-
dure
[110]
that was used several times in
the literature, problems that occured du-
ring the purification process of the pro-
duct could not be solved. TLC analy-
sis showed the formation of a fluorescent
product, but it could not be purified by application of the described chro-
matographic procedures and was too sensitive for HPLC. Adjusting the
eluent polarity for chromatography did not result in improved separa-
tion.
Very similar reaction conditions were used to synthesize an alkyne
functionalized BODIPY dye using 5-hexinoyl acid chloride and 2,4-di-
methylpyrrole (Figure 3.9).
[111]
This time the difficulties in separation
could be solved successfully by crystallization from toluene and petrol
ether.
[112]
The alkyne was then clicked to an azido carboxylic acid to yield
the desired BODIPY dye.
Figure 3.9: Synthesis of BODIPY dye 23. a) DCM, reflux, 2 h; b) 5 eq. BF3·OEt2, 4 eq.
DIPEA, rt, on, 15 %; c) 1 eq. 3-azidopropionic acid, 1 eq. Cu powder, ACN, H2O, rt,
4 d, 73 %.
.
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To test the generality of our orthogonal probe assembly approach, mo-
lecule 1b was synthesized. Notably, this novel route affords the design
of application-tailored parallel synthesis of other ABPs since resin 24 can
be stored in the fridge for several months without quality loss. It fea-
tures two orthogonal attachment sites for the inhibitory moiety and the
reporter group. This allows for parallel synthesis of desired conjugates
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upon the design of a biochemical experiment with its individual require-
ments. Probe 1a was prepared in solution with inevitable purification af-
ter each step.
[107]
This could be reduced to preparative HPLC at the end
of the synthesis of 1b which drastically reduced synthesis time. The bi-
otinylated probe was deliberately prepared to widen the range of possible
applications of sulfatase QM probes. Using the on-resin synthetic route
different inhibitors and reporter groups like fluorophores or isotopic la-
bels can be easily combined to synthesize probe libraries. In this context
probe 1b was synthesized as a model probe for future derivatives; biotin
was added via peptide coupling, and the alkynyl inhibitory QM fragment
was coupled by CuAAC (Figure 3.10).
Figure 3.10: Synthetic pathway for the solid phase synthesis of QM type probe 1b. a) 3 eq.
biotin, 3 eq. TBTU, 6 eq. DIPEA, DMF, rt, 2 h; b) 1 eq. alkyne 15, 12 eq. sodium ascorbate,
24 eq. CuI, DMF, rt, on; c) 20 % (v/v) HFIP, DCM, rt, 60 min, 29 %; d) activated Zn dust,
MeOH, PBS pH 7.2, rt, 5 d, 39 %.
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3.3.2 Cyclic Sulfamate Probes
Following the initial plan to compare two different ABPPs for sulfatases,
the cyclic sulfamate 2b was synthesized with an additional alkyne group
following a literature procedure for the sulfamate moiety.
[9]
There are two
key steps in this synthetic sequence. First, the introduction of the tosyl
protection needs to be monitored closely by TLC to maximize product
yield. The reaction has to be worked up immediately after completion to
circumvent severe product losses. The base also plays an important role,
as triethylamine leads to tosylation of the phenolic oxygen atom which
can be hardly distinguished from the desired amine protection by NMR-
spectroscopy.
[113]
Figure 3.11: Synthesis of alkyne 2b. a) Pd/C, H2, MeOH, rt, 4 h, 99 %; b) 1.2 eq.
TsCl, DCM/Pyridin = 1:1, 4 ◦C, 1 h, 96 %; c) 2 eq. propargylamine, 2.8 eq.
EDC·HCl, 2.8 eq. HOBt·H2O, 3.8 eq. NMM, DCM, rt, 50 h, 32 %; d) 3 eq. SO2Cl2,
4 eq. TEA, DCM, -78 ◦C, 2 h, 30 %; e) NaN3, ACN:MPW = 1/1, rt, 3.5 h, quant.
Second, generation of the cyclic sulfamate only proceeds well under dry
conditions and at constantly low temperatures. A prominent side reac-
tion that occurs at slightly elevated temperatures when applying sulfuryl
chloride to aryl compounds is the chlorination of the ring.
[114]
CySA alkyne 2c which features a slightly different linker was also syn-
thesized. The incorporated amine alkyne linker 32 was prepared follow-
ing standard procedures as depicted in Figure 3.12. Its coupling to acid 27
proceeded with a yield of 28 % which is very similar to the coupling yield
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of amide 28. Formation of the cyclic sulfamate 34 could be improved by
23 % compared to the synthesis of 29 by elongation of the reaction time.
Removal of the tosyl group gives probe precursor 2c.
Figure 3.12: Synthesis of amine alkyne linker 32 and para-alkyne 2c. a) 0.8 eq. Boc2O, 2.5 eq.
NaOH, ACN/H2O = 1:1, 4 ◦C–rt, 24 h, 85 %; b) 1.1 eq. NaH, 1.1 eq. propargylbormide, THF,
4 ◦C–reflux–rt, 48 h, 60 %; c) DCM/TFA = 4:1, rt, 1 h, quant.; d) 0.5 eq. acid 27, 1.0 eq. EDC·HCl,
1.0 eq. HOBt·H2O, 2.5 eq. pyridine, DCM, rt, 50 h, 28 %; e) 3 eq. SO2Cl2, 4 eq. TEA, DCM,
-78 ◦C, 4 h, 53 %; f) NaN3, ACN:MPW = 1/1, rt, 3.5 h, quant.
.
.
.
.
.
.
.
.
.
.
. .
For inhibition studies and as a negative control for labeling experiments
the original inhibitor CySA 2a without a linker or reporter group was also
synthesized according to literature.
[9]
3.3.3 Azido Reporter Groups and in situ CuAAC
Figure 3.13: Synthesis of clickable cyanine
dye 37. a) 4 eq. 1,3-dibromopropane,
ACN, reflux, 4 h, 80 %; b) 2.5 eq. NaN3,
ACN, reflux, 17 h, quant.; c) 1 eq. 4-(di-
methylamino)benzaldehyde, cat. piperidine,
EtOH, 60 ◦C, 16 h, 83 %.
For clickable inhibitors 2b and c two dif-
ferent reporter groups were synthesized: a
cyanine dye and biotin both derivatized
as azides. The cyanine dye 37 was cho-
sen due to its facile synthesis according
to literature
[115,116]
as well as its interest-
ing spectroscopical properties. The reac-
tion route as depicted schematically in Fig-
ure 3.13 was straight-forward and featured
no unexpected challenges. Purification of
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the intermediates 35 and 36 was not necessary, and the final product
37 could be purified by two consecutive flash chromatographies. Yields
were similar to the literature even though we used dibromo- instead of
diiodopropane in the first step.
Compared to other labels like fluorescein or a BODIPY-dye which were
both previously synthesized and applied for activity-based probes in our
hands, the isolated overall yield and the ease of purification represented a
great improvement. Cyanine dye 37 features some special properties that
are particularly useful for biochemical applications. Its absorption maxi-
mum at 480 nm and emission maximum at 600 nm with a high extinction
coefficient of 47,000 M−1· cm−1 [115] account for the extremely large Stokes
shift which makes 37 a perfect fluorophore for FRET approaches. Addi-
tionally, the high quantum yield and stability against photobleaching are
advantageous for fluorescence microscopy.
Figure 3.14: Synthesis of click-
able biotin 39. a) 3 eq. NaN3,
H2O, 75 ◦C, 21 h, 67 %; b)
0.83 eq. NHS-biotin, 2 eq. TEA,
DMF, rt, 16 h, quant.
For sulfatase pull-down, the biotin derivative 39
was synthesized according to literature.
[117]
The azi-
doethylamine 38 was prepared from the chloro- in-
stead of the bromoethylamine which might account
for the 15 % lower yield. It has to be handled very
carefully since azide derivatives with such low ratios
of carbon to nitrogen are potent explosives.
[118]
The
second step is carried out slightly different compared
to literature
[117]
regarding equivalents of azide 38 and
TEA which improved the yield of azide 39 by 25 %.
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Figure 3.15: CuAAC reaction of biotin azide 39 and
CySA alkyne 2b. a) 1 mM alkyne 2b, 1 mM azide 39,
1 mM sodium ascorbate, 1 mM TBTA, 1 mM CuSO4,
PBS/MeOH/DMSO = 1:2.8:1.4, rt, 1 h, 47 %.
The CuAAC reaction was carried
out following a protocol espe-
cially optimized for in situ activity-
based proteomics applications in
water.
[119]
This procedure makes
use of the TBTA ligand that has
been described to enhance the yield
of Cu(I) catalyzed click reactions
in water.
[120]
The purpose of this
small-scale reaction was to estab-
lish a click protocol in our lab
which can be transferred to the in
situ labeling of sulfatases. In this respect the reaction was successfully
expanded to our system. Analytical HPLC comparison of 2b, 39 and the
crude reaction mixture clearly show that no starting material remained
after one hour. Preparative HPLC yields 47 % of pure product 2d.
3.3.4 Conclusion of Sulfatase Probe Synthesis
In conclusion we generated two sets of probe building blocks which were
combined to form new sulfatase probes. For QMs a novel approach was
developed; alkynylated monofluoromethylphenyl inhibitor 15 and repor-
ter groups that were functionalized as carboxylic acids (biotin and BODI-
PY dye 23) could be joined orthogonally by solid phase assembly. As
a proof of concept we successfully synthesized the biotinylated probe
1b. For CySA probes we decided to delay attachment of the inhibitor to
the reporter group until the biochemical labeling process had transpired.
Therefore, alkynylated CySAs 2b and 2c as well as azido-bearing reporter
groups 37 and 39 were synthesized. CuAAC reaction conditions from the
literature
[119]
were successfully adapted to our building blocks for the
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synthesis of probe 1d. Therefore, in situ labeling should now be feasible
with CySA probes.
3.4 Biochemical Evaluation of Quinone Methide
Type Probes
Broad-range inhibitory function toward the members of a targeted en-
zyme class can be an important property of activity-based probes. With
the synthesized sulfatase probes, different activity states of known hu-
man and bacterial sulfatases should be investigated. Moreover, unknown
sulfatases from plants might be detected and identified by future experi-
ments if probes with a wide-range binding motif are available.
To test the generality of our quinone methide precursors, we tested a
panel of sulfatases: recombinantly expressed and purified cysteine- and
serine-type aryl sulfatases from bacteria (PARS
[9]
and KARS
[121]
), human
aryl sulfatase G (ARSG
[122]
) and steroid sulfatase (STS
[123]
). Each has
distinct features: the bacterial sulfatases are active against a broad range
of aryl sulfate substrates under basic (pH of 8.9 for PARS) and neutral
(pH 7.5 for KARS) conditions; STS is a membrane-bound sulfatase of the
endoplasmic reticulum or resident in the Golgi lumen with neutral pH
optimum and a high specificity for steroid sulfates; and ARSG is a newly
discovered lysosomal enzyme, with acidic pH optimum and unknown
biological substrate and function.
[7]
To evaluate the applicability of QM probes it is important to consider
sulfatase inhibition versus QM formation and inactivation. These crite-
ria for characterizing QM precursor probes were addressed by 19F-NMR
measurements (Figure 3.17) which have previously been used to defini-
tively investigate the elimination of fluoride and thereby the generation
of QMs.
[50,51]
Sulfatase inhibition was investigated by dose-dependent
51
3 Targeting Sulfatases
(Figure 3.18a-c) and time-dependent (Figure 3.18d and 3.19) activity as-
says. Sulfatase labeling performance of QM precursor probes was tested
by means of 2D-GEs and subsequent fluorescence scans (Figure 3.20, 3.21
and 3.23) as well as mass spectrometry of labeled proteins (Figure 3.24
and 3.25).
3.4.1 19F-NMR Experiments
Figure 3.16: QM probe precursor 1c
The cleavage of the sulfate ester of probe pre-
cursor 1c by KARS, PARS, ARSG and STS was
monitored in real-time using 19F-NMR spec-
troscopy. Upon hydrolysis of the sulfate ester
by the enzyme, fluoride is eliminated and appears as a new signal at
δ = -120 ppm. After a reaction time of about twelve hours the conver-
sion ceased for KARS which implies complete enzyme inhibition at this
point (Figure 3.17). Controls verified that KARS remained active under
the applied conditions without addition of inhibitor.
Figure 3.17: Time-dependent 19F-NMR spectrum
of fluoride generation triggered by KARS-mediated
sulfate cleavage of QM precursor 1c. The new sig-
nal at a shift of -120 ppm is assigned to the released
fluoride.
The ratio of integrals of probe-bound
fluorine and liberated fluoride indi-
cated that about 20 % of the probe
were converted before KARS was fi-
nally inactivated. Considering the
2000-fold excess of QM precursor 1c
over KARS it is obvious that the in-
hibition is inefficient. Approximately
400 molecules of probe were con-
verted by one KARS enzyme before
it was deactivated.
Various reasons for this lack of effi-
ciency can be put forward. Either the
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QM is deactivated before it binds active site residues of KARS or it binds
in a way that enzyme activity is preserved. In the latter case, more
than one QM would react per protein, as has been reluctantly discussed
earlier.
[48,51,124]
Alternatively, diffusion of QM out of the active site before
covalent bond formation might occur, and the probe could then be inac-
tivated by any nucleophile on the protein surface or of the surrounding
medium. This process would lead to a high degree of undesired back-
ground protein labeling.
While KARS and PARS cleaved the sulfate ester readily, as can be seen
exemplarily for KARS in Figure 3.17, the human enzymes ARSG and
STS did not. The respective integrals of the 19F-NMR signals of the in-
tact probe did not change, and no new fluoride signals arose in either
of the two spectra. One reason why the human enzymes did not cleave
1c might be a drastically reduced turnover due to structural differences
in comparison to the natural substrates of these enzymes. From pseudo-
substrates for assaying sulfatase activities it is known that ARSG prefers
substrates with an additional hydroxyl group in ortho position to the sul-
fate ester.
[122]
STS, however, has been shown to turn over small aryl sul-
fates like 1c. Another possibility that could not be excluded is enzyme
inactivation due to unfavorable conditions (i.e. too low protein concen-
tration, too low buffer concentration, adhesion of the enzyme to the glass
walls of the NMR tube). The final concentrations and activities of the hu-
man enzymes in the NMR-samples were too low to assess their activity
by sulfatase activity assay.
Substrate cleavage from QM precursor probes has been previously
investigated by 19F-NMR-spectroscopy.
[50,51]
Those probes contained a
phosphate ester or a β-glycoside which were cleaved by the enzymes
tyrosine phosphatase PTP-1B and β-glycosidase, respectively. Although
probe to protein ratios exceeded 10,000:1 a complete turnover of the pro-
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bes was observed in both cases. Probes with such a low inhibitory effi-
ciency should rather be considered as pseudo-substrates not inhibitors.
Compared to these results it is obvious that the sulfatase QMs presented
in this work are at least capable of completely inhibiting the bacterial en-
zymes under the tested conditions.
3.4.2 Inhibition Studies
For QM probes it is important to distinguish between sulfate cleavage of
the ester moiety and actual binding to and inhibition of the investigated
enzyme. The results of QM formation obtained from 19F-NMR experi-
ments were supported by sulfatase activity assays. Complete inhibition
of KARS could be achieved after 30 minutes preincubation with 10 mM
probe 1c which corresponds to a ratio of KARS to probe of approximately
1:4000 (Figure 3.18a). PARS was only partially inactivated at the applied
QM precursor concentrations (Figure 3.18b). However, it is very likely
that it is completely inactivated at higher concentrations.
In contrast to that, the activity of ARSG remained nearly unaffected
at all tested conditions even upon overnight incubation (Figure 3.18c).
The human enzyme STS was also only partially inhibited. The time-
dependence of inhibition was pronounced for STS as can be seen in Figure
3.18d. It is striking that STS was inhibited by QM precursors but did not
generate QMs in 19F-NMR experiments. Apparently, the experimental
conditions of the NMR measurements led to enzyme inactivation inde-
pendent of inhibitor addition.
STS and ARSG inactivations were measured after preincubation at 37 ◦C
to mimic native conditions. However, STS inhibition was not temperature-
dependent when comparing residual activities after incubation for four
hours at room temperature and at 37 ◦C. For all enzymes, residual actives
are reported as a percentage of the uninhibited control, and all measure-
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ments were done in triplicate. Error bars are standard deviations between
individual measurements
Figure 3.18: Inhibition of a) KARS, b) PARS and c) ARSG by probe precursor 1c at
different concentrations. d) Time-dependent inhibition of STS by 1 mM 1c.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Figure 3.19: Time- and concentration-
dependent inhibition of KARS by 1c.
Time-dependent inactivation of enzymes can
be seen if active site residues are involved
in QM capture.
[104]
This was exemplarily as-
sessed by time- and concentration-dependent
inhibition of KARS by QM precursor 1c. A de-
pendency of both time and concentration can
clearly be seen in Figure 3.19. However, a
determination of the kinetic parameters kinact
and Ki using the Kitz-Wilson method
[104]
usu-
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ally applied for mechanism-based inhibition is not possible. Kitz-Wilson
methodology requires time-dependent measurement of initial substrate
conversion rates at different inhibitor concentrations. Using pNCS as
the pseudo-substrate of sulfatase activity determination, residual activity
needs to be monitored at pH 10 which terminates sulfatase activity and
leads to end point activity measurement.
3.4.3 Labeling Results
The next step was to extend the application of QM probes to their des-
ignated purpose i.e. the selective labeling of sulfatases in complex mix-
tures. To directly assess probe activation and selectivity, we opted for
three model proteomes containing an active sulfatase, an inactive sulfa-
tase and no sulfatase. These proteomic samples consisted of crude lysates
from E. coli DH5α cells which expressed
1. recombinant KARS together with its post-translational activating
enzyme AtsB
[121]
(Figure 3.20a),
2. recombinant KARS alone, which will remain inactive without AtsB
(Figure 3.20b), and
3. no sulfatase (null vector control, Figure 3.20c).
E. coli lysate provides a non-sulfatase protein background, as it does not
have any known endogenous sulfatases whereas human lysates natively
contain active sulfatases.
[121]
KARS was chosen as the model sulfatase
to be labeled since it shows QM substrate activity in the low mM range,
which is representative of the biological Km of most human sulfatases.
The lysates were labeled with 1 mM probe 1a for 60 min. Respective
sulfatase activity and inactivities were confirmed via pNCS assays be-
fore labeling. The labeled samples were then separated by 2D-GEs. The
fluorescence scans (left panel) show light spots for each labeled protein
56
3.4 Biochemical Evaluation of Quinone Methide Type Probes
with several horizontal spots due to modifications that influence protein
pI. Coomassie stains of the gels containing active (Figure 3.20a), inactive
(3.20b) and no sulfatase (3.20c) are also depicted and show about the same
amount of protein (50 µg as determined by Bradford assay) were loaded
on the gels.
Figure 3.20: Fluorescence (left panel)
and corresponding coomassie-stained
(right panel) images of the 2D-GEs of
probe 1a-labeled E. coli lysates. The
purple box indicates KARS.
This experiment clearly proves the necessity of
active sulfatase for QM labeling. The fluores-
cence scans of E.coli lysate containing inactive
KARS and wildtype E. coli lysate (Figure 3.20b
and c, left panel) both lack fluorescent proteins.
All three scans were developed for ten minutes,
and the tone value was narrowed digitally be-
yond the usual range for the scans containing no
active sulfatase to definitely visualize all labeled
proteins. The bright cloud in the lower left cor-
ner of 3.20c is caused by excess of probe. Ini-
tial labeling experiments with inactive sulfatase
expressing E. coli cells failed due to the low ex-
pression rates so that the inactive sulfatase was
not visible in the coomassie stains of these gels.
Low expression of inactive KARS has been pre-
viously observed
[125]
and might be attributed to
formation of inclusion bodies. This problem was
evaded by purification of inactive KARS and
spiking of the lysate to approximately the same
level as for the active sulfatase in Figure 3.20a. The fact that nearly no
labeling was observed in the control samples even when scanning for 20
minutes and covering the area containing excessive probe proves that ac-
tive sulfatase is crucial for labeling.
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A lack of specificity for QM probe 1a was demonstrated by this experi-
ment as most of the background proteins also show up in the fluorescence
scan of active sulfatase lysate. One obvious conclusion to be drawn from
these findings is that the QM precursor probe 1a which is cleaved and
activated by the sulfatase subsequently dissociates out of the active site,
while still in its reactive form. Consequently, the QM-fluorescein conju-
gate binds to other proteins in the solution.
To verify that this is not a unique characteristic of KARS, cell lysate of
STS-overexpressing cells was investigated. STS was expressed as previ-
ously described
[40,123]
by Eva Ennemann (BCI, Bielefeld University) and
then labeled with 1 mM of probe 1a for 60 min at 37 ◦C. The sample was
separated by 2D-GE, and labeled proteins were detected by fluorescence
scanning (Figure 3.21a).
Figure 3.21: Labeling of STS-expressing cell lysate with probe 1a. The sample was
separated by 2D-GE a) fluorescence scan of the gel, b) α-STS western blot c) α-FGE
western blot.
It becomes evident that just as for KARS-lysate many proteins were la-
beled and therefore fluorescent. STS and FGE were visualized by western
blotting (WB) with an intermediate stripping step (Figure 3.20b and c;
blotting was done by Eva Ennemann, BCI, Bielefeld University). STS was
not transferred to the IPG strip as it is a membrane-associated protein,
and therefore it could not be detected by WB (Figure 3.20b). The presence
of the soluble luminal ER protein FGE was detected by WB which serves
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as an indicator for successful blotting. This experiment verifies the un-
specific nature of QM-labeling: the sulfatase mainly responsible for QM
generation was not transferred into the gel, hence, all visible spots are
due to diffused QMs.
Figure 3.22: Fluorescence and corresponding
coomassie-stained images of the 2D-GE of probe
1a-labeled KARS-enriched E. coli lysate. The
purple frames mark the identified protein spots.
To further investigate the nature of
background protein labeling, a KARS-
enriched E. coli lysate was used to deter-
mine whether higher abundance of sul-
fatase influences specificity of labeling.
Incubation with probe 1a was done ex-
actly as described for the other E. coli
lysates. A number of the background
proteins were identified by LC-MS/MS
analysis of tryptic digests as indicated by
the purple frames in Figure 3.22. The re-
sults support unspecificity of background labeling since these proteins
do not share common properties concerning structure, function or active
site composition. By comparing labeling as detected in the fluorescence
scan (left panel, Figure 3.22) with abundance as visualized by coomassie
staining (right panel, Figure 3.22) of spots 8 and 9, it becomes clear that
labeling does not merely correlate with abundance. Even the content of
cysteine residues which are the preferred labeling sites of QM probes
[55]
cannot be directly correlated to the amount of labeling (compare Figure
3.22 and Table 3.1). Most probably, a mixture of factors like accessibility
of cysteine side chains or other less reactive nucleophiles and abundance
determines protein labeling efficiency.
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Table 3.1: Proteins identified via tryptic digestion and LC-MS/MS analysis.
Sequence Cysteine
Spot Protein Coverage Residues
1 KARS 46 % 0
2 Pyruvate kinase I 41 % 6
3 Glutamate decarboxylase α 30 % 9
4 Serine hydroxymethyltransferase 42 % 3
5 Phosphoglycerate kinase 50 % 3
6 Glyceraldehyde-3-phosphate dehydrogenase A 53 % 3
7 Chaperone protein hchA 34 % 2
8 Elongation factor Ts 40 % 2
9 Transaldolase B 30 % 3
Figure 3.23: Fluorescence and respective
coomassie-stained gel images of KARS-
labeling with probe 1a at increasing con-
centrations of ethanolamine.
Attempts were made to reduce the amount
of unspecific labeling by addition of small-
molecule nucleophiles (i.e. ethanolamine) to
trap any diffused activated species. Prepuri-
fied KARS was used which features a high ra-
tio of sulfatase to background protein. Label-
ing was conducted as described for 2D-GE ex-
periments. Unfortunately, the addition of ethanolamine also resulted in
decreased labeling of KARS, again supporting that labeling is of a non-
specific origin (Figure 3.23).
Even more evidence for the non-specific nature of QM-labeling was
gathered by MS studies of probe 1c-labeled PARS and KARS. Whole pro-
tein was submitted to MALDI-ToF/ToF analysis and a clear shift of pro-
tein weight by at least around 550 Da was detected for PARS (Figure 3.24).
This corresponds to about two modifications for each protein with a sin-
gle modification resulting in a mass increase of 280 Da.
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Figure 3.24: Overlay of MALDI-
ToF/ToF spectra of PARS, labeled
PARS and a 1:1 mixture of both
samples.
Only little unmodified PARS was detected as the
whole protein peak shifted and this finding pro-
vides another strong clue for unspecific labeling.
It is impossible that the whole population of en-
zyme in the sample was in its active state before
labeling. The peak also broadens considerably in-
dicating a wide mass distribution with up to ten
modifications per protein accounting for an ave-
rage mass shift of about 2 kDa.
The same effect was observed when labeling
KARS with probe 1c. KARS is expressed with a
cleavable N-terminal propeptide which leads to
three main masses even without addition of QM precursor. Therefore,
the spectrum is more complicated to analyze and not as conclusive as for
PARS.
Figure 3.25: QM labeling sites of PARS (1HDH,
RCSB protein data base) incubated with probe
1a. Active site residues, labeled peptides.
These MS results prompted us to try
and map exact QM targeting sites to
the three-dimensional protein structure
of PARS. QM 1c-labeled and tryptically
digested PARS peptides were identified
using LC-MS/MS analysis. The data
was scanned by Mascot MS/MS search
and annotated using the in-house soft-
ware QuPE.
[126]
The QM modification
was searched as a variable mass addi-
tion to possibly all amino acid residues.
The sample was unambiguously identified as PARS with a Mascot score
above 2000 and about 70 % sequence coverage. Three labeled peptides
were identified (Figure 3.25), although, there are most likely more which
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are too low abundant and hence not detected. Importantly, these three
peptides were not identified in control samples of non-labeled PARS.
The position of labeling within the peptide sequences could not be as-
signed since their MS/MS fragmentation patterns were not complete. The
location of labeled peptides within the protein clearly supports our hy-
pothesis of QM diffusion after sulfate ester cleavage since these peptides
are too far from the active site for labeling to have occurred without prior
diffusion. In our opinion labeling results in a heterogenous distribution
of peptides with differing masses. The discrete peptides form low abun-
dant populations and are therefore hard to detect via LC-MS/MS studies
of crude tryptic digests.
By labeling KARS with the biotinylated probe 1b, the biotinylated pep-
tides should be enriched using streptavidin beads. This could lead to a
more precise mapping of QM binding sites within the 3D-structure of the
protein. The labeled sample and a non-labeled control were both sepa-
rated by 2D-GE. Spots in the region of KARS were cut out and the pep-
tides obtained after trypsination were applied to streptavidin beads. No
protocol was available to elute peptides from the beads which is compat-
ible with LC-MS/MS analysis. Therefore, TFA was applied to denature
streptavidin and elute all bound peptides. Even though the success of
biotinylation was monitored by streptavidin blotting of a 2D-GE of 1b-
labeled KARS, no peptides were detected in LC-MS/MS analysis. Either
they were not eluted from the beads using TFA, other substances were
coeluted and evaded detection of labeled fragments, or the distribution
of labeled peptides is too heterogenous for single molecules to stick out.
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3.4.4 Conclusion of QM-Type Probe Experiments
In conclusion, our results support the assumption that sulfatase-genera-
ted QMs are most likely stable enough to diffuse from the active site. Un-
der these circumstances the electrophilic position of the QM is attacked
by any other nucleophile different form an active side chain of the actual
target enzyme. Sulfatase QM probes were only useful to detect sulfatase
activities but there are cheaper commercially available pseudo-substrates
for this purpose.
Several other studies about QM probes only examine and prove label-
ing of purified proteins
[51,53,55,56]
or unspecific labeling was ignored.
[8,48]
Both practices are misleading. The successful application of QM precur-
sor probes for the selective labeling of enzymes in complex mixtures still
remains to be proven. The only successful example of a specific QM-
based probe was recently published for protein tyrosine phosphatase.
[47]
The authors added a peptide sequence to the probe to increase binding
specificity to their target enzyme. It must be stated however, that this
probe only targets one enzyme within the class of protein tyrosine phos-
phatases. Therefore, it is not useful for general ABP problems like moni-
toring up- and down-regulation of a whole enzyme family or identifica-
tion of new enzymes.
3.5 Cyclic Sulfamates as Sulfatase Targeting
Groups
Cyclic sulfamates were biochemically investigated for their dose-depen-
dent inhibitory action on various sulfatases. Their inhibitory mechanism
was partially elucidated via PARS active site labeling and LC-MS/MS
analysis of labeled and tryptically digested samples. First experiments of
labeling purified PARS as well as KARS and STS in a more complex mix-
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tures were followed by in situ labeling of STS with subsequent CuAAC
reaction to couple the reporter group.
3.5.1 Inhibition Experiments
Figure 3.26: Structures of cyclic sulfamates
2a and 40 as well as linear sulfamate 41.
In comparison to the panel of sulfatases
used to evaluate QM precursor probe 1c, in-
hibition by CySA 2a, CySA 40 and linear
sulfamate (LiSA) 41 was assessed with two
additional human sulfatases. Thereby, wide applicability at comparable
inhibitor concentrations should be demonstrated.
Figure 3.27: Inhibition of five different sulfatases by
CySA 2a and 40 as well as LiSA 41.
As can be seen in Figure 3.27,
the two bacterial sulfatases PARS
and KARS are better inhibited by
all tested molecules than the hu-
man enzymes which seem to be
more specific and less tolerable to-
wards non-native substrates. The
only exception was inhibition of
ARSA by CySA 2a. For the bac-
terial sulfatases inhibitor 2a dis-
plays weaker inhibitory properties
requiring mM concentrations in contrast to 40 and 41 which show satis-
fying results at high µM concentrations.
The three human sulfatases tested respond differently to the panel of
inhibitors used in this study. The linear phenyl sulfamate 41 is at the
same time the most effective inhibitor and the least sterically demanding.
However, due to the postulated inhibitory mechanism (Figure 3.4) this
molecule is not believed to be useful for activity-based proteomics appli-
cations since it most certainly would eliminate its label. Comparing the
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two cyclic sulfamates 2a and 40, it becomes evident that 2a is the more
potent inhibitor for ARSA, ARSB and STS.
In summary, cyclic sulfamate 2a was chosen for incorporation into our
probes. It was active against all tested sulfatases at low mM concentra-
tions which is what we opted for. Unfortunately, time- and concentration-
dependent inhibition studies to determine kinetic parameters of binding
could not be recorded since the inhibition process was too fast to be accu-
rately monitored.
3.5.2 Investigation of the Inhibitiory Mechanism
To further understand the mechanism of CySA inhibition several exper-
iments were conducted. First, it was investigated whether the FGly resi-
due was covalently modified by inhibiting PARS with CySA 2a before la-
beling with an aldehyde addressing fluorophore. Additionally, cyanogen-
bromide digestion of CySA 2a-labeled PARS was used to detect any new
peptides. These new conjugates could be generated by substitution of the
enzyme-inhibitor intermediate by an internal Schiff-base formed with a
lysine residue. Lastly, 2a-labeled tryptic digests of PARS were analyzed
via LC-MS/MS to identify labeling sites and dead-end adducts.
Figure 3.28: Structures of fluorescein-5-thiosemi-
carbazide and Alexa Fluor R© 488 hydroxylamine.
The irreversible inactivation of ac-
tive sites is an important property
of activity-based probes. The ques-
tion of whether cyclic sulfamates
were able to modify sulfatase FGly
residues covalently and quantita-
tively was addressed by application
of aldehyde and ketone directed flu-
orescent probes as depicted in Figure 3.28. The infrequent occurrence of
aldehydes and ketones in biomolecules has stimulated the development
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of these probes to selectively introduce fluorescent labels. Various meth-
ods have been developed to first insert a carbonyl function into proteins,
thus providing unique sites for chemical modification and greatly extend-
ing the possibilities of these probes.
[127]
For our application we used the
dyes depicted in Figure 3.28: fluorescein-5-thiosemicarbazide and Alexa
Fluor R© 488 hydroxylamine.
Figure 3.29: Reaction of a fluorescent hydrazine derivative as shown above with an
aldehyde or ketone to form a) a hydrazone derivative or b) an oxime.
The semicarbazone formed with the semicarbazide (as seen in Figure
3.29a) as well as the O-substituted oxime formed with the hydroxylamine
(Figure 3.29b) during the labeling reactions can be stabilized by reduction
with NaCNBH3 to avoid elimination of the label. Notably, NaCNBH3
does not reduce aldehyde functions.
Figure 3.30: Fluorescence scan
(left panel) and coomassie stain
(right panel) of Alexa Fluor R©
488 hydroxylamine-labeled PARS.
1) PARS; 2) reduced PARS; 3)
PARS with 20 mM CySA 2a;
4) reduced PARS with 20 mM
CySA; 5) 20 µg PARS with
20 mM CySA 2a.
The result of PARS active site modification by CySA
2a can be seen in Figure 3.30. For this particular exper-
iment, 5 µg PARS were incubated with 20 mM CySA
2a to investigate whether the active site is irreversibly
modified by this inhibitor class. Inactivity of prein-
hibited samples was verified with 4-MUS activity as-
says. To prove that oxime stabilization by treatment
with NaCNBH3 after labeling does not alter the out-
come we also treated PARS with NaCNBH3 before la-
beling with the Alexa dye overnight. We also applied
a bigger amount of labeled PARS (20 µg) to detect any
residual fluorescence. The samples were separated on
a 1D-GE and fluorescence was measured. Lanes 1 and
2 show the labeling of FGly by the Alexa dye. Inhibi-
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tion with cyclic sulfamate 2a suppresses this labeling completely as seen
in lanes 3–5. It is evident that CySA modifies FGly residues quantitatively
and irreversibly. The coomassie stain clearly indicates equal amounts of
protein were loaded for all samples.
To investigate the nature of active site modification, we labeled PARS
with CySA 2a until complete inhibition and then digested the sample
with cyanogenbromide (CNBr). This yields relatively large peptide frag-
ments which can be separated by 1D-GE, as CNBr only cleaves after me-
thionine residues. One hypothetical dead-end product of CySA inhibition
is a Schiff-base formed by substitution of the enzyme-CySA intermediate
with the N of a conserved lysine residue situated within the active site
of sulfatases. To stabilize this potential Schiff-base, the inhibited sample
was treated with NaCNBH3 before the digest was initiated by addition
of CNBr. After resolution by electrophoresis, no new peptide bands were
detected. We therefore concluded that the FGly modification that evades
labeling with the Alexa dye in Figure 3.30 was due to a covalently bound
inhibitor and not a newly created intramolecular bond.
The samples used for the Alexa-labeling were also trypsinated in so-
lution and analyzed via LC-MS/MS by Dr. S.R. Hanson (TSRI, La Jolla).
The results strongly indicate a covalent modification of the tryptic pep-
tide containing the active site FGly residue. Spectral counts of all other
peptides remained unaffected by CySA inhibition, only the number of the
detected FGly-containing peptide species went down to about 0–10 % of
the non-labeled control. However, no dead-end adducts were detected
in these experiments, probably, due to the sensitive nature of the CySA-
enzyme bond.
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3.5.3 Preliminary Sulfatase Labeling Results
Figure 3.31: CySA-biotin conjugate 2e.
For first visualization and labeling stu-
dies biotinylated CySA 2e as depicted
in figure 3.31 was used (provided by Dr.
S.R. Hanson, TSRI, La Jolla). This probe
allows for enrichment of labeled proteins by interaction of the biotin moi-
ety with streptavidin-coated sepharose beads. 5 µg of PARS were labeled
with 20 mM probe 2e. As negative controls the protein was preincubated
with CySA 2a and LiSA 41. The results of this experiment are shown in
Figure 3.32. Beads enrichment, SDS-GE and western blotting were con-
ducted by Dr. S.R. Hanson (TSRI, La Jolla).
Figure 3.32: Coomassie stain (left) and α-
biotin blot (right) of CySA 2e labeled PARS.
1-4) flow-through; 5-8) beads elutions. 1, 5)
0 mM probe 2e; 2, 6) 20 mM probe 2e; 3, 7)
preincubation with 20 mM CySA 2a before
20 mM 2e; 4, 8) preincubation with 20 mM
SA 41 then 20 mM 2e.
The first four lanes of both gel and blot cor-
respond to the supernatant of streptavidin
beads. Lanes 5–8 depict the respective pro-
teins eluted from the beads by boiling. The
sample without probe (lanes one and five)
does not bind to the beads and is not visu-
alized on the blot. PARS treated with the bi-
otinylated probe binds to the beads as can
be seen both in the coomassie stain as well
as in the blot. PARS seen in lane two of
the coomassie stain is only slightly visible in
the streptavidin blot. This might be inactive
protein possibly lacking the post-translational modification of the FGly
residue which was therefore not labeled by 2e. Samples applied to lanes
three and four were preincubated with inhibitors and displayed about
15 % and 0 % residual activity, respectively. This might explain the slight
amount of labeling seen in the blot. However, much less protein is la-
beled, bound and eluted in these preinhibited samples. It is striking that
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the inhibitory potency of CySA 2a and LiSA 41 towards PARS (compare
Figure 3.27) does not correlate with residual labeling. The better inhibitor
41 allows for more binding of probe 2e. This could be due to a different
binding mode of the linear versus the cyclic inhibitor 2d, the latter seems
to form a more stable covalent adduct than LiSA 41.
Since the labeling results of purified PARS were promising, we ex-
tended the same protocol to HT1080 cells expressing STS. Crude cell lysate
was first incubated with the same set of inhibitors before addition of
probe 2e. Subsequently, the biotinylated proteins were enriched via strep-
tavidin beads, the samples were split for separation on two SDS-GEs for
silver staining and for western blotting.
Figure 3.33: Silver stained gel (left),
streptavidin (middle) and α-His blot
(right) of a streptavidin pull-down ex-
periment of STS-expressing HT1080
cell lysate labeled after incubation with
probe 2e. 1) no probe; 2) 20 mM 2e;
3) preincubation with 20 mM CySA
2a; 4) preincubation with 20 mM LiSA
41.
The silver stain shows nearly no protein bound
unspecifically to the streptavidin beads as can be
seen in lane 1 in the left panel. The highest amount
of protein bound to the sample without preincu-
bation with other inhibitors (lane 2, left panel).
However, considerable amounts of protein bound
to the probe after treatment with both CySA 2a
and LiSA 41 (lanes 3 and 4, left panel). From the
inhibition tests we already knew that treatment
with 20 mM CySA 2a prior to probe 2e incubation
might not completely suppress STS activity (Fig-
ure 3.27) and LiSA 41 inhibition already proved
not to prevent probe 2e binding in PARS label-
ing experiments (Figure 3.32). Therefore, it is not surprising that protein
shows up in these lanes.
The streptavidin blot clearly confirms these results, as it shows the
amount of protein biotinylation is highest in lane 2 of the middle panel.
The α-His blot shows the amount of STS in all four samples. So even few
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protein can be detected in the sample that was not treated with probe 2e
in the silver stain and streptavidin blot (lane 1, middle), it does contain
some STS. The membrane-associated sulfatase is expressed at very low
levels in human cell culture and is well detected in the selective α-His
blot. In comparison, it becomes evident that probe 2e is able to enrich
STS (lane 2, right panel) and just as for PARS, preincubation with CySA
2a and LiSA 41 does not completely reduce labeling. Even though these
results look promising, further experiments are necessary to reduce the
amount of unspecifically labeled proteins and investigate the nature of
residual binding. Several mechanisms could account for the residual la-
beling as observed in lanes three and four (right panel, Figure 3.32). The
activated species might diffuse out of the active site as was proven for
QM-type probes, the inhibitor used for preincubation does not inhibit co-
valently or preinhibition was not complete. Most probes exhibit some
amount of unspecific binding and require optimization of their labeling
protocol.
Figure 3.34: CySA-coumarin conjugate 2f.
For a better comparison of the speci-
ficity of QM and CySA labeling, we used
CySA-coumarin 2f (provided by Dr. S.R.
Hanson, TSRI, La Jolla) to label KARS-
enriched E. coli lysate (Figure 3.35). The
same protocol was used as for the fluo-
rescein derivative 1a. Compared to Figure 3.22, fluorescence is weaker
due to technical limitations of the CCD camera used for detection. The
coumarin dye of probe 2f requires different excitation and emission wave-
lengths which the camera does not feature.
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Figure 3.35: Fluorescence scan and coomassie stain of
CySA 2f-labeled KARS-enriched E. coli lysate.
Under these conditions CySA-
labeling seems to be more spe-
cific than the QM-labeling but
no definite conclusion should be
drawn from these preliminary
results at this point. Further ex-
periments might be visualized
using a Typhoon scanner with a
wider variety of excitation and
emission wavelengths. How-
ever, since only a limited amount of the probe 2f was supplied (from
Dr. S.R. Hanson, TSRI, La Jolla), the experiment could only be conducted
twice.
More and more activity-based proteomic studies make use of in situ
CuAAC reactions of inhibitor moieties and reporter groups. There are
many advantages if the fluorescent dye is attached after the labeling event
has occurred. The inhibitor alone is not sensitive to photobleaching so
that the labeling process is less critical for the later detection. Another
advantage is that the alkynylated probe precursors are much smaller and
therefore more likely to diffuse through membranes. It is important which
component bears the alkyne and which the azide function. Studies have
shown that the alkyne is not completely bioorthogonal so that the label
should bear the azide to avoid elevated levels of background binding.
[119]
For our first experiments with in situ CuAAC we used a previously pub-
lished protocol which makes use of the TBTA ligand to improve the yield
of this reaction in buffer systems.
[73]
71
3 Targeting Sulfatases
Figure 3.36: Fluorescence scan (left
panel) and corresponding coomassie
stain (right panel) of 2b-labeled STS-
expressing HT1080 cell lysate reacted
with the reporter group 37. 1) 0 mM
2b; 2) 0.1 mM 2b; 3) 0.5 mM 2b;
4) 1 mM 2b; 5) preincubation with
10 mM CySA 2a before addition of
5 mM 2b.
STS-expressing HT1080 cells were lysed and then
labeled with different concentrations of alkynyl-
ated CySA 2b. No probe 2b and preincubation
with CySA 2a served as the negative controls.
Similar to Figure 3.33 there is a band at about
70 kDa that is clearly labeled in a dose-dependent
manner. Unfortunately, the identity of the other
proteins visible in the fluorescence scan could not
be investigated by tryptic digest and LC-MS/MS.
They were either endogenously expressed sulfa-
tases or other proteins that were unspecifically la-
beled. As for the other labeling experiments these
results need further optimization and verification.
3.5.4 Conclusion of Cyclic Sulfamate Probe Investigations
In conclusion, CySA 2 probes are promising tools for the activity-based
analysis of sulfatases. They are general inhibitors in mM concentrations
of a wide range of sulfatases (Figure 3.27). The mechanism of inhibition
was not fully elucidated. However, we were able to prove that CySAs are
covalent inhibitors that target the active site FGly residue (Figure 3.30).
First labeling studies were promising for future applications like fluores-
cence microscopy and the investigation of samples with unknown sulfa-
tases.
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3.6.1 Synthesis of Quinone Methide Precursor Probe 1b
2-Acetoxy-2-(4-acetoxyphenyl)acetic acid (11)
4-Hydroxymandelic acid (1.11 g, 6.57 mmol) was dissolved in 6 mL pyri-
dine and cooled to 0 ◦C. 2 mL of Ac2O were added and the reaction mix-
ture was stirred for 30 min at 0 ◦C. The solvent was removed in vacuum
and the residue was dissolved in 20 mL DCM. The product was acidi-
fied with 10 mL of 2 M HCl and the phases were separated. The organic
layer was dried over Na2SO4 and after evaporation of DCM in vacuum,
product 11 was obtained as a colorless solid (1.42 g, 5.61 mmol, 86 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.20 (s, 3H, CH3), 2.32 (s,
3H, CH3), 5.95 (s, 1H, CHOC), 7.12 (m, 2H, Har), 7.50 (m, 2H, Har), 9.99
(s br, 1H, COOH).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 20.6 (CH3), 21.1 (CH3), 73.4
(CHOC), 122.1 (Car), 128.9 (Car), 130.7 (Car), 151.4 (CarO), 169.3 (C=O),
170.3 (C=O), 173.8 (COOH).
2-Acetoxy-2-(4-acetoxyphenyl)-N-(2-propynyl)acetamide (12)
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Carboxylic acid 11 (1.42 g, 5.61 mmol) was dissolved in 60 mL DCM and
282 µL (4.40 mmol) propargylamine, 2.01 g (10.5 mmol) EDC·HCl and
2.23 mL (16.1 mmol) TEA were added. After stirring overnight at rt, the
mixture was washed with 2 M HCl (1 × 30 mL) and brine (1 × 30 mL)
before drying over Na2SO4. Evaporation in vacuum yielded 12 as a co-
lorless solid (1.47 g, 5.07 mmol, 90 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.19 (s, 3H, CH3), 2.26 (t,
1H, 4J = 2.5 Hz, C≡CH), 2.30 (s, 3H, CH3), 4.05-4.19 (m, 2H, CH2), 6.11 (s,
1H, CHOC), 6.49 (s br, 1H, NH), 7.10 (m, 2H, Har), 7.45 (m, 2H, Har).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 21.0 (CH3), 21.1 (CH3), 29.2
(CH2), 72.2 (C≡CH), 74.3 (CHOC), 78.9 (C≡CH), 122.0 (Car), 128.8 (Car),
132.8 (Car), 151.2 (CarO), 167.8 (C=O), 169.0 (C=O), 169.3 (C=O).
2-Hydroxy-2-(4-hydroxyphenyl)-N-(2-propynyl)acetamide (13)
1.44 g (4.90 mmol) of amide 12 were dissolved in 50 mL MeOH. The so-
lution was cooled to 0 ◦C before slowly adding 80 mL 2 M NaOH and
stirring for 3 h. The reaction was acidified to a pH of 1-2 with 2 M HCl.
The mixture was washed with DCM (4 × 50 mL) and the aqueous phase
was lyophilized. The residue was adsorbed to Celite for flash chromato-
graphic separation (EA/n-hexanes = 2:1). The product 13 was obtained
as a colorless oil (164 mg, 0.08 mmol, 17 %).
1H-NMR (500 MHz, CDCl3, D4-MeOH, TMS): δ [ppm] = 2.38 (m, 1H,
C≡CH), 4.03 (m, 2H, CH2), 4.96 (s, 1H, CHOH), 6.79 (m, 2H, Har), 7.23
(m, 2H, Har).
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13C-NMR (126 MHz, CDCl3, D4-MeOH, TMS): δ [ppm] = 28.9 (CH2), 71.7
(C≡CH), 73.9 (CHOH), 79.2 (C≡CH), 115.6 (Car), 128.3 (Car), 130.8 (Car),
157.2 (CarOH), 173.8 (CONH).
MS (ESI): m/z = 204.0 (calcd. 204.1 for [M-H]−), 240.0 (calcd. 240.0 for
[M+Cl]−).
4-(1-Hydroxy-2-oxo-2-(2-propynylamino)ethyl)phenyl 2,2,2-trichloro-
ethyl sulfate (14)
Alcohol 13 (60 mg, 0.27 mmol) was dissolved in 60 mL DCM, and 39 mg
(0.32 mmol) DMAP as well as 54 µL (0.39 mmol) TEA were added. 239 mg
(0.97 mmol) 2,2,2-trichloroethyl chlorosulfate were dissolved in 10 mL
DCM and added dropwise over 10 h to the reaction mixture. The so-
lution was stirred for further 9 h at rt before it was washed with water
(1 × 30 mL), 5 % (w/v) KHSO4 (3 × 30 mL), 10 % NaHCO3 (w/v) (2 ×
30 mL) and brine (2 × 30 mL). The organic layer was dried over Na2SO4
and the crude product was adsorbed to Celite for flash chromatographic
purification (EA/PE = 1:1) to give 14 as a colorless oil (102 mg, 0.24 mmol,
91 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.26 (m, 1H, C≡CH), 3.64 (s,
1H, OH), 3.98-4.17 (m, 2H, NHCH2), 4.85 (s, 2H, CCl3CH2), 5.07 (s, 1H,
CHOH), 6.71 (s br, 1H, NH), 7.36 (m, 2H, Har), 7.51 (m, 2H, Har).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 29.2 (NHCH2), 72.1 (C≡CH),
73.2 (CHOH), 78.7 (C≡CH), 80.4 (CCl3CH2), 92.3 (CCl3), 121.4 (Car), 128.5
(Car), 138.8 (Car), 150.0 (CarOS), 171.0 (CONH).
MS (ESI): m/z = 413.9 (calcd. 413.9 for [M-H]−), 451.8 (calcd. 451.9 for
[M+Cl-H]−).
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4-(1-Fluoro-2-oxo-2-(2-propynylamino)ethyl)phenyl 2,2,2-trichloro-
ethyl sulfate (15)
80 mg (0.19 mmol) of compound 14 were dissolved in 5 mL DCM and
cooled to -20 ◦C. 49 µL (0.37 mmol) DAST were added and the mixture
was stirred for 1 h at -20 ◦C followed by 14 h at rt. 1 mL MeOH was
added and stirred for 10 min before removal of the solvent in vacuum.
The crude product was purified by flash chromatography (DCM/MeOH
= 35:1) to yield 15 as a colorless oil (56 mg, 0.13 mmol, 70 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.30 (t, 1H, 4J = 2.5 Hz,
C≡CH), 4.03-4.21 (m, 2H, NHCH2), 4.72-4.90 (s, 2H, CCl3CH2), 5.83 (d,
1H, 2J = 47.7 Hz, CHF), 6.71 (s br, 1H, NH), 7.40 (m, 2H, Har), 7.57 (m, 2H,
Har).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 29.1 (NHCH2), 72.4 (C≡CH),
78.4 (C≡CH), 80.5 (CCl3CH2), 90.6 (d, 1J= 190.8 Hz, CHF), 92.3 (CCl3),
121.4 (Car), 128.3 (d, 3J = 6.9 Hz, CarCHF), 134.2 (d, 2J = 19.4 Hz, Car),
150.6 (CarOS), 167.5 (d, 2J = 20.7 Hz, CONH).
19F-NMR (471 MHz, CDCl3, CFCl3 external): δ [ppm] = -181.5 (d, 2J =
48.2 Hz, CHF).
Probe 1b Assembly
Preloaded resin 24 was synthesized under standard peptide chemistry
conditions. Briefly, 1 g of 2-chlorotrityl resin (loading capacity 1 mmol/g)
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was loaded by reacting 1.5 mmol Fmoc-Lys(Alloc)-OH and 6 mmol DI-
PEA in DCM to give a total loading of 0.90 mmol/g resin. Side-chain
Alloc-deprotection was achieved using 6 eq. phenylsilane and 0.1 eq.
Pd(PPh3)4 in DCM under argon atmosphere. Coupling of 3-azidopro-
pionic acid was done with 3 eq. each of the acid and TBTU and 6 eq. of
DIPEA in DCM. Fmoc-cleavage was accomplished using 4 % (v/v) piperi-
dine and 4 % (v/v) DBU in DMF. To couple biotin, 3 eq. of the acid, 3 eq.
TBTU and 6 eq. DIPEA were dissolved in DMF and added to the resin
with occasional stirring for 2 h at rt. The CuAAC proceeded with 1 eq.
alkyne 15, 12 eq. sodium ascorbate and 24 eq. CuI in DMF under ar-
gon atmosphere over night. All steps were monitored by MALDI-ToF-
MS analysis. The resin was treated with 20 % (v/v) HFIP in DCM, and
the product was purified by preparative HPLC to give 26b as a colorless
solid (25.7 mg, 0.029 mmol, 29 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 1.21-1.91 (m, 12H, CH2),
2.30 (m, 2H, CH2CO), 2.72 (m, 1H, SCH2a), 2.81 (m, 2H, CH2CO), 2.93 (m,
1H, SCH2b), 3.09-3.22 (m, 3H, SCH, CH2), 4.31 (m, 1H, CHbiotin), 4.44 (m,
1H, CHbiotin), 4.47-4.58 (m, 3H, CH2, CHCOOH), 4.63 (t, 2H, 3J = 6.6 Hz,
NCH2CH2CO), 4.91 (s, 2H, CH2CCl3), 5.82 (s, 1H, 2J = 47.7 Hz, CHF), 7.42
(m, 2H, Har), 7.58 (m, 2H, Har), 7.68 (s, 1H, CHN).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 22.9 (CH2), 25.8 (CH2),
28.1 (CH2), 28.7 (CH2), 31.2 (CH2), 34.5 (CH2), 35.5 (CH2), 36.0 (CH2),
39.2 (CH2), 40.6 (CH2S), 41.6 (CH2NH), 46.7 (CH2NN), 52.2 (CHCOOH),
55.9 (CHS), 60.4 (CHbiotin), 61.9 (CHbiotin), 80.7 (CCl3CH2), 90.6 (d, 1J =
189.7 Hz, CHF), 92.6 (CCl3), 121.6 (Car), 123.9 (Ctriazole), 128.8 (d, 3J =
6.9 Hz, Car), 135.1 (d, 2J = 19.5 Hz, Car), 144.2 (Ctriazole), 150.8 (CarOS),
164.7 (NHCONH) 169.0 (d, 2J = 23.0 Hz, CONH), 170.2 (CONH), 174.9
(CONH), 175.0 (COOH).
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19F-NMR (471 MHz, CDCl3, CFCl3 external): δ [ppm] = -180.5 (d, 2J =
47.6 Hz, CHF).
For the final deprotection of the sulfate ester 22 mg (0.025 mmol) of
the probe 26b were dissolved in MeOH/PBS pH 7.28 = 1:1 and 1 g HCl-
activated zinc dust was added. The reaction proceeded very slowly over
five days until reaction monitoring via MALDI-ToF showed no further
starting material. Zinc powder was removed by filtration over Celite and
the crude product was purified by preparative HPLC to give probe 1b as
a colorless solid (7 mg, 0.010 mmol, 40 %).
MS (ESI-FT-ICR): m/z = 377.11125 (calcd. 377.10936 monoisotopic mass
for [M-H]2−).
3.6.2 Synthesis of Cyclic Sulfamate Probe Components
Pyridinium-2-(4-hydroxy-3-(N-tosyl)phenyl)acetic acid 27
2-(3-Nitro-4-hydroxyphenyl)acetic acid (4.99 g, 25.31 mmol) was dissol-
ved in 150 mL MeOH, a pinch of Pd/C was added, and Ar was bubbled
through the suspension for 15 min. Then the atmosphere was exchanged
by H2 and the reduction was allowed to proceed under stirring for 4 h
at rt until no starting material was detected by TLC (DCM/MeOH = 9:1).
The precipitated product was dissolved by addition of 150 mL acetic acid,
Pd/C was removed by filtration over Celite, and removal of the solvents
in vacuum yielded the amine as a light brown solid (4.23 g, 25.29 mmol,
99 %)
587 mg (3.51 mmol) of the amine were dissolved in 20 mL of DCM/
pyridine = 1:1 and the mixture was cooled to 4 ◦C. 1.2 eq. of tosylchloride
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(794 mg, 4.24 mmol) were added and the reaction was stirred for 60 min
at rt. The solvent was removed by coevaporating twice with toluene. The
pyridinium salt 27 was obtained as a colorless solid (1.35 g, 3.37 mmol,
96 %) after flash chromatography (DCM/MeOH = 9:1).
TLC (DCM/MeOH = 9:1): Rf = 0.26.
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.34 (s, 3H, CH3), 3.46 (s,
2H, CH2), 6.68 (m, 1H, Har), 6.85 (m, 1H, Har), 7.18 (m, 2H, Har), 7.24
(m, 1H, Har), 7.35 (m, 2H, Hpyridinium), 7.64 (m, 2H, Har), 7.76 (m, 1H,
Hpyridinium), 8.55 (m, 2H, Hpyridinium).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 21.5 (CH3), 40.5 (CH2),
115.5 (Car), 123.5 (Car), 124.3 (Car), 124.4 (Car), 126.0 (Car), 126.9 (Car),
127.4 (Car), 129.5 (Car), 136.0 (Car), 137.1 (Car), 143.8 (Car), 147.6 (Car),
149.0 (Car), 174.7 (COOH).
MS (ESI): m/z = 319.9 (calcd. 320.3 for [M-H-pyridinium]−).
N-(2-Propynyl)-2-(4-hydroxy-3-(N-tosyl)phenyl)acetamide 28
The pyridinium salt 27 (1.35 g, 3.37 mmol) was dissolved in 23 mL DCM.
To this solution 1.1 eq. HOBt·H2O (502 mg, 3.72 mmol), 3.2 eq. NMM
(1.15 mL, 10.29 mmol), 1.1 eq. EDC·HCl (711 mg, 3.71 mmol) and 1.6 eq.
propargylamine (344 µL, 5.43 mmol) were added, and it was stirred at
rt for 36 h. The mixture was washed with 0.1 M HCl (3 × 10 mL), and
the product precipitated as a colorless solid in the organic layer. This
was filtered, taken up in EA and crystallized from DCM to give 28 as a
colorless solid (333 mg, 0.93 mmol, 29 %).
TLC (DCM/EA = 9:1): Rf = 0.4.
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1H-NMR (500 MHz, D4-MeOH): δ [ppm] = 2.35 (s, 3H, CH3), 2.60 (t, 1H,
4J = 2.6 Hz, C≡CH), 3.35 (s, 2H, CH2), 3.94 (d, 2H, 3J = 2.5 Hz, NHCH2),
6.62 (m, 1H, Har), 6.85 (m, 1H, Har), 7.25 (m, 3H, Har), 7.63 (m, 2H, Har).
13C-NMR (126 MHz, D4-MeOH): δ [ppm] = 21.5 (CH3), 29.7 (NHCH2),
42.8 (CH2), 72.4 (C≡CH), 80.6 (C≡CH), 116.2 (Car), 125.3 (Car), 125.8
(Car), 127.7 (Car), 127.9 (Car), 128.5 (Car), 130.4 (Car), 138.1 (Car), 144.9
(Car), 149.8 (Car), 173.9 (COOH).
2-(1-Tosyl-2,2-dioxo-benzo[d ]-1,2,3-oxathiazole-5-yl)-N-(2-propynyl)
acetamide 29
The alkyne 28 (333 mg, 0.93 mmol) was dissolved in 20 mL DCM/DMF =
3:1, and 4 eq. TEA (541 µL, 3.88 mmol) were added at rt. The solution was
cooled to -78 ◦C then 3 eq. sulfurylchloride (213 µL, 2.63 mmol) in 4 mL
DMF were added over 2 h. The suspension was warmed to 0 ◦C, and
washed with water. The aqueous phase was extracted with 50 mL DCM,
and the combined organic phases were washed with brine and dried over
Na2SO4. After removal of the solvent the brown oil was subjected to
flash-chromatography (DCM/EA = 9:1) to yield 29 as a colorless solid
(117 mg, 0.28 mmol, 30 %).
TLC (DCM/EA = 9:1): Rf = 0.3.
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.30 (t, 1H, 4J = 2.4 Hz,
CH2C≡CH), 2.42 (s, 3H, CH3), 3.57 (s, 2H, CH2), 4.03 (s, 2H, NHCH2),
7.03 (m, 1H, Har), 7.15 (m, 1H, Har), 7.35 (m, 2H, Har), 7.64 (m, 1H, Har),
7.88 (m, 2H, Har).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 21.8 (CH3), 29.4 (NHCH2),
42.5 (CH2), 71.6 (C≡CH), 79.4 (C≡CH), 112.0 (Car), 116.4 (Car), 126.2
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(Car), 127.4 (Car), 129.0 (Car), 130.3 (Car), 132.4 (Car), 133.2 (Car), 140.2
(Car), 147.3 (Car), 170.6 (C=O).
MS (ESI): m/z = 443.0 (calcd. 443.5 for [M+Na]+).
N-(2-Propynyl)-2-(2,2-dioxo-benzo[d ]-1,2,3-oxathiazole-5-yl)acet-
amide 2b
The cyclic sulfamate 29 (117 mg, 0.28 mmol) was suspended in 7.5 mL
ACN/H2O = 4:1. After addition of 1.5 eq. NaN3 (28 mg, 0.43 mmol),
the starting material dissolved completely, and the reaction was stirred
for 2.5 h at rt until TLC (EA/n-hexanes/AcOH = 7:3:0.1) showed nearly
complete turnover. Additional 12 mg (0.19 mmol) of NaN3 were added
to the mixture, and it was stirred for another hour at rt. The solvents
were removed in vacuum and the residue was taken up in 10 mL water.
The pH was adjusted to 2 using 0.1 M HCl, and the aqueous phase was
extracted with EA (3 × 10 mL). The combined organic phases were dried
over Na2SO4. The solvent was removed and the residue was purified by
flash chromatography (EA/n-hexanes/AcOH = 7:3:0.1). The product 2b
(85 mg, 0.28 mmol, quant.) was obtained after coevaporating twice with
toluene.
TLC (EA/n-hexanes/AcOH = 7:3:0.1): Rf = 0.3.
1H-NMR (500 MHz, D6-acetone): δ [ppm] = 2.64 (t, 1H, 4J = 2.5 Hz,
C≡CH), 3.54 (s, 2H, CH2), 3.98 (m, 2H, NHCH2), 7.03 (m, 1H, Har), 7.09
(m, 1H, Har), 7.15 (m, 1H, Har).
13C-NMR (126 MHz, D6-acetone): δ [ppm] = 30.1 (NHCH2), 43.8 (CH2),
73.1 (C≡CH), 82.2 (C≡CH), 112.4 (Car), 115.3 (Car), 125.6 (Car), 132.1
(Car), 134.8 (Car), 143.8 (Car), 171.5 (C=O).
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MS (ESI): m/z = 266.9 (calcd. 267.3 for [M+H]+), 288.9 (calcd. 289.3 for
[M+Na]+).
MS (ESI-FT-ICR): m/z = 289.02522 (monoisotopic mass calcd. 289.02535
for [M+Na]+ deviation 0.45 ppm).
O-tert-Butyl-N-(2-hydroxyethyl)carbamate 30
2-Aminoethanol (5.09 g, 52.13 mmol) was dissolved in 100 mL ACN/H2O
= 1:1 cooled to 4 ◦C, and 2.5 eq. NaOH (5.20 g, 130 mmol) were added.
Then 0.8 eq. Boc2O (9.45 g, 43.30 mmol) were added. The reaction was
stirred at 4 ◦C for 30 min and then at rt overnight. The pH was adjusted
to 7 using 5 % (w/v) KHSO4, and the product was extracted with EA
(4 × 30 mL). The combined organic phases were washed with 5 % (w/v)
KHSO4 (2 × 30 mL) dried over Na2SO4, and the solvent was removed in
vacuum to yield 30 as a yellow oil (5.9 g, 36.8 mmol, 85 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 1.45 (s, 9H, CH3), 2.56 (s,
1H, OH), 3.28 (m, 2H, CH2), 3.69 (t, 2H, 3J = 5.0 Hz, CH2), 5.04 (s, 1H,
NH).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 14.1 (CH3), 40.7 (NCH2),
61.0 (OCH2), 115.5 (C(CH3)3), 143.4 (C=O).
MS (ESI): m/z = 184.00 (calcd. 184.20 for [M+Na]+).
O-tert-Butyl-N-(2-propynyloxy)ethylcarbamate 31
1.1 eq. NaH (1.60 g, 40 mmol) were suspended in 100 mL THF and
cooled to 4 ◦C. Carbamate 30 (5.90 g, 36.7 mmol) in 100 mL THF and
1.1 eq. propargylbromide (6.0 g, 40 mmol) in 50 mL THF were added.
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The reaction was refluxed for 10 min and then stirred at rt for 48 h. The
mixture was then diluted with water, and THF was removed in vacuum.
The aqueous phase was extracted with EA (4 × 30 mL), and the com-
bined organic phases were washed with brine (1 × 30 mL), dried over
Na2SO4, and the solvent was removed in vacuum. The product 31 (5.80 g,
29.2 mmol, 60 %) was obtained as a yellow oil after flash chromatography
(DCM/EtOH = 30:1).
TLC (DCM/EtOH = 10:1): Rf = 0.8.
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 1.45 (s, 9H, CH3), 2.45 (m,
1H, CH), 3.35 (d, 2H, 3J = 5.0 Hz, CH2), 3.59 (t, 2H, 3J = 5.0 Hz, CH2), 4.16
(d, 2H, 4J = 1.8 Hz, CH2C≡CH), 4.92 (s, 1H, NH).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 28.4 (CH3), 40.3 (NCH2),
58.2 (OCH2), 69.1 (OCH2), 74.6 (≡CH), 79.3 (C(CH3)3), 79.4 (C≡CH),
155.9 (C=O).
2-(2-Propynyloxy)ethylammonium trifluoroacetate 32
Carbamate 31 (4.30 g, 21.6 mmol) was dissolved in 200 mL DCM/TFA =
4:1 and stirred at rt for 1 h. The product was coevaporated twice with
toluene and then lyophilized to give 32 (5.00 g, 23.3 mmol, quant.) as a
yellow oil after flash chromatography (DCM/EtOH = 30:1).
TLC (DCM/EtOH = 10:1): Rf = 0.1.
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.51 (t, 1H, 4J = 2.5 Hz,
CH2C≡CH), 3.21 (s, 2H, CH2), 3.77 (t, 2H, 3J = 5.0 Hz, CH2), 4.20 (m, 2H,
CH2), 8.00 (s, 3H, NH3).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 39.4 (NCH2), 58.3 (OCH2),
65.0 (OCH2), 75.6 (≡CH), 78.5 (C≡CH).
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N-(2-(2-Propynyloxy)ethyl)-2-(4-hydroxy-3-(N-tosyl)phenyl)acet-
amide 33
Amine 32 (271 mg, 2.00 mmol) was dissolved in 5 mL DMF. 0.5 eq. HOBt·
H2O (135 mg, 1.00 mmol), 2.5 eq. pyridine (400 µL, 5.00 mmol), 0.5 eq.
EDC·HCl (192 mg, 1.00 mmol) and 1.7 eq. carboxylic acid 27 (389 mg,
1.21 mmol) were dissolved in 2 mL of DMF and added to the reaction
mixture before stirring at rt overnight. DMF was removed under vac-
uum, and the residue was taken up in DCM, washed with 0.5 M HCl
(3× 10 mL), 10 % (w/v) NaHCO3 (3× 10 mL), and brine (1× 10 mL). The
organic phase was dried over Na2SO4, and the solvent was removed in
vacuum. Column chromatography (n-hexanes/iPrOH = 6:1) yielded 33
as a colorless solid (114 mg, 0.28 mmol, 28 %).
1H-NMR (500 MHz, CDCl3, TMS): δ [ppm] = 2.32 (s, 3H, CH3), 2.48 (t,
1H, 4J = 2.3 Hz, C≡CH), 3.33 (s, 2H, CH2CO), 3.46 (m, 2H, CH2NH), 3.61
(t, 2H, 3J = 5.1 Hz, OCH2), 4.14 (d, 2H, 4J = 2.4 Hz, CH2C≡CH), 7.03 (m,
1H, Har), 7.16 (m, 2H, Har), 7.18 (m, 1H, Har), 7.61 (m, 2H, Har), 8.05 (m,
1H, Har).
13C-NMR (126 MHz, CDCl3, TMS): δ [ppm] = 21.7 (CH3), (NCH2), 58.5
(OCH2), 64.5 (OCH2), 68.3 (C≡CH), 75.2 (C≡CH), 123.7 (Car), 124.5 (Car),
126.0 (Car), 127.4 (Car), 127.5 (Car), 129.6 (Car), 129.7 (Car), 136.0 (Car),
144.0 (Car), 148.1 (Car), 172.7 (C=O).
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2-(1-Tosyl-2,2-dioxo-benzo[d ]-1,2,3-oxathiazole-5-yl)-N-(2-(propargyl-
oxy)ethyl)acetamide 34
The alkyne 33 (114 mg, 0.28 mmol) was dissolved in 6 mL DCM, and 4 eq.
TEA (157 µL, 1.13 mmol) were added at rt. The solution was cooled to
-78 ◦C and 3 eq. sulfurylchloride (69 µL, 0.85 mmol) in 2 mL DCM were
added over 2 h. The reaction mixture was stirred at -78 ◦C for further
90 min, then it was diluted with 10 mL DCM/H2O = 1:1. The phases were
separated, and the aqueous phase was extracted with DCM (2 × 20 mL).
The combined organic phases were dried over Na2SO4. After removal of
the solvent the product was subjected to flash-chromatography (DCM/
EA = 3:1) to yield 4 as a colorless solid (70 mg, 0.15 mmol, 53 %).
TLC (DCM/EA = 9:1): Rf = 0.3.
N-(2-(Propargyloxy)ethyl)-2-(2,2-dioxo-benzo[d ]-1,2,3-oxathiazole-5-
yl)acetamide 2c
The cyclic sulfamate 34 (50 mg, 0.11 mmol) was suspended in 6.5 mL
ACN/H2O = 4:1. After addition of 1.2 eq. NaN3 (9 mg, 0.13 mmol), the
starting material dissolved completely, and the reaction was stirred for
16 h at rt. ACN was removed, the pH of the solution was adjusted to 2
with 1 M HCl, and the aqueous phase was extracted with EA (3× 10 mL).
The combined organic phases were dried over Na2SO4. The solvent was
removed, and the residue was purified by vacuum filtration over silica
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gel (eluent: EA). The product 2c (35 mg, 0.11 mmol, quant.) was obtained
as a colorless solid after coevaporating twice with toluene.
1H-NMR (500 MHz, D4-MeOH): δ [ppm] = 2.83 (t, 4J = 2.4 Hz, 1H, C≡CH),
3.37 (t, 3J = 5.3 Hz, 2H, NHCH2), 3.49 (s, 2H, CH2CO) 3.57 (t, 3J = 5.5 Hz,
2H, CH2O), 4.15 (d, 4J = 2.5 Hz, 2H, CH2C≡CH), 6.94-6.97 (m, 2H, Har),
7.04-7.10 (m, 1H, Har).
13C-NMR (126 MHz, D4-MeOH): δ [ppm] = 40.4 (CH2CO), 43.2 (NHCH2),
58.8 (OCH2), 69.1 (CH2O), 76.0 (C≡CH), 80.5 (C≡CH), 111.6 (CarH), 114.0
(CarH), 124.4 (CarH), 132.0 (Car), 133.9 (CarNH), 143.5 (CarO), 173.7 (C=O).
N-(2-(4-(((2,2-Dioxo-benzo[d ]-1,2,3-oxathiazol-5-yl)acetamido)me-
thyl)-1H-1,2,3-triazole-1-yl)ethyl)biotinamide 2d
3.11 mL of a 5 mM solution of alkyne 2b in MeOH, 3.11 mL of a 5 mM
solution of biotin azide 39 in MeOH, and 3.11 mL 5 mM TBTA in DMSO
were combined. To this solution 0.6 mL 54 mM ascorbate and 0.6 mL
47 mM CuSO4 both in water were added. The pH of the resulting suspen-
sion was adjusted with 1 mL PBS pH 7.2, and the reaction was allowed to
proceed for 1 h at rt before lyophilization. The resulting colorless residue
was taken up in ACN/H2O = 1:1 and purified by preparative HPLC to
give 2d as a colorless solid (4.2 mg, 0.007 mmol, 47 %).
1H-NMR (600 MHz, D4-MeOH): δ [ppm] = 1.36 (m, 4H, C=OCH2CH2-
CH2CH2), 1.64 (m, 4H, C=OCH2CH2CH2CH2), 2.14 (m, 2H, C=OCH2-
CH2CH2CH2), 2.70 (m, 1H, SCH2a), 2.93 (dd, 1H, 2J = 5.0 Hz, 3J = 12.7 Hz,
SCH2b), 3.19 (m, 1H, SCH), 3.50 (s, 2H, C=OCH2,ar), 3.62 (t, 2H, 3J =
5.8 Hz, NCH2CH2NHC=O), 4.30 (dd, 1H, 2J = 4.4 Hz, 3J = 7.8 Hz, SCHCH),
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4.43 (s, 2H, NHCH2,triazole), 4.48 (m, 3H, SCH2CH, NCH2CH2NHC=O),
6.97 (m, 2H, Har), 7.09 (m, 1H, Har), 7.79 (s, 1H, CHtriazole).
MS (ESI-FT-ICR): m/z = 579.18193 (monoisotopic mass calcd. 579.18025
for [M+H]+ deviation 2.91 ppm.
3.6.3 Biochemical Evaluation of QM Precursors
19F-NMR Measurements
19F-NMR real-time investigations of QM sulfate cleavage were conducted
with KARS containing E. coli lysate, PARS, STS containing HT1080 cell
lysate and ARSG. All experiments were performed in regular NMR tubes
at 37 ◦C on a Bruker Avance 600. After an initial 19F-NMR spectrum of
probe 1c was recorded, the respective enzymes were added, and fluo-
ride liberation was followed by continuous NMR measurements for up
to 14 d.
Table 3.2: Sample compositions for 19F-NMR measurements of 1c turnover by
various sulfatases.
Concentration Inhibitor 1c
Enzyme or Lysate Volume Concentration Buffer in D2O
KARS 10 µL; 70 nM 140 µM 500 µL 10 mM Tris pH 7.5
PARS 70 µM 5 mM 600 µL 100 mM Tris pH 8.0
STS 20 µL 5 mM 500 µL 10 mM Tris pH 7.2
ARSG 3 nM 5 mM 500 µL 0.5 M NaAcOH pH 5.6
Inhibition Assays of Arylsulfatases
Turnover of pNCS by sulfatases to p-nitrocatechol (pNC) was measured
by absorbance at 515 nm after stopping the enzyme reactions with 0.33 M
NaOH. All measurements were performed in triplicate and repeated twice.
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KARS (1 µM, in 50 mM Tris, pH 7.5, 250 mM NaCl) or PARS (1 µM, in
50 mM Tris, pH 8.5) were incubated for various times with different con-
centrations of inhibitor 1c in 10 µL assay volume at room temperature.
After preincubation, the sulfatase activity assay was initiated by adding
pNCS to a final volume of 310 µL with a final assay composition of 35 nM
sulfatase, 8 mM pNCS and 8 mM Tris (at pH 7.5 or pH 8.5, for KARS and
PARS, respectively). The enzyme reaction was allowed to proceed for
10 min at room temperature before quenching by addition of 600 µL 1 M
NaOH. For ARSG the assay was conducted as follows: ARSG (20 nM,
in 0.5 M NaOAc, pH 5.6) was incubated with 1c for 3 h and for 18 h at
37 ◦C. Sulfatase activity assay was then initiated by adding pNCS to a fi-
nal concentration of 8 mM in 0.5 M NaOAc, pH 5.6, with a total volume
of 150 µL, and the enzyme was allowed to react for 60 min at 37 ◦C. The
reaction was stopped by addition of 150 µL 1 M NaOH.
Steroidsulfatase Activity Assay as Conducted by E. Ennemann
STS lystate (5 µL) was preincubated with inhibitor 1c for 0, 1, 2 and 4 h
at 37 ◦C with different concentrations of 1c in 50 mM Tris, pH 7.4 (final
volume of 47.5 µL). STS activity was determined using 3H-Dehydroepi-
androsterone-3-sulfate (3DHEAS) as substrate.
[123,128]
The reaction was
started by adding DHEAS to a final concentration of 5 µM containing
25,000 cpm 3H-DHEAS (kindly supplied by Bernhard Schmidt, Institut
für Biochemie II, Universität Göttingen) in a final volume of 50 µL. Af-
ter 10 min of incubation at 37 ◦C the reaction was stopped by addition of
25 µL 1 M NaOH. Radioactivity of the product 3H-DHEA was detected
by liquid scintillation counting as previously described.
[123]
All measure-
ments were done in triplicate and repeated twice.
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Time- and Concentration-Dependent Inhibition Studies
KARS was incubated with different concentrations of QM precursor 1c
from 10–60 min time intervals at rt before measuring residual activity
with pNCS as described above. The measurements were conducted as
triplicates and repeated twice.
Fluorescence-Labeling Studies
50 µg prepurified KARS was incubated with 1 mM probe 1a in 35 mM
Tris pH 7.2, 140 mM NaCl, 3.5 mM CaCl2 for 60 min in the dark at rt in
a total volume of 20 µL. The sample was diluted and submitted to 2D-
GE as described in section 5.3.1. Visualization of the fluorescence signal
was achieved using in-gel fluorescence detection with a CCD-camera (ex-
citation at λ = 460 nm, detection at λ = 515 nm). Selected spots were cut
out from the gel and tryptic digestion was carried out as described in
section 5.3.2. The samples were lyophilized, and stored at -20 ◦C until
LC-MS/MS measurement. Labeling and LC-MS/MS runs were repeated
twice to prove reproducibility of results.
Labeling with QM precursor 1a in the presence of competitive nucle-
ophile was conducted with enriched KARS lysate. 5 µg of protein were
labeled with 1 mM of probe 1a for 60 min in the presence of different con-
centrations of ethanolamine. Protein was separated on a 1D-SDS-GE and
visualized as described in section 5.3.1.
MS Analysis of labeled PARS and KARS as Conducted in Coopera-
tion with B. Müller
MALDI-ToF MS measurements of labeled PARS and KARS were per-
formed on an ultrafleXtreme mass spectrometer (Bruker Daltonik). The
spectra were acquired in the linear mode. 5000 single spectra were sum-
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marized with a 1 kHz smartbeam-II laser for each sample. Spectral pro-
cessing (smoothing and baseline subtraction) was done in flexAnalaysis
(Bruker Daltonik). 10 µg purified KARS and PARS were labeled at rt
with 5 mM 1c in a total volume of 20 µL for 1 and 12 h, respectively.
For MALDI-ToF MS analysis: 2 µL of the labeling mixture were mixed
with 2 µL of 2 % (v/v) TFA and 2 µL of matrix solution (7.6 mg 2,5-
dihydroxyacetophenone dissolved in 375 µL EtOH and 125 µL of a so-
lution containing 18 mg/mL aqueous diammonium hydrogen citrate so-
lution). The protein-matrix mixture (0.5 µL) was spotted onto a ground
steel target for MALDI-Tof MS analysis.
LC-MS/MS analysis was done with protein spots from gels depicted in
Figure 3.22. The samples were digested and analyzed as described in sec-
tion 5.3.2. Protein identification was performed with MASCOT MS/MS
ion search (Matrixscience) against the SwissProt-database (search para-
meters: taxonomy: proteobacteria, instrument: ESI-TRAP, 2 missed clea-
vage sites, variable modifications: oxidation (M), carbamidomethyl (C),
peptide tolerance: 1000 ppm, MS/MS tolerance: 500 mmu, peptide charge:
+1,+2,+3 monoisotopic, significance threshold (p<): 0.05, automatic sco-
ring) and annotated with the in-house program QuPE
[126]
(FDR thresh-
old: 0.05, minimal number of hits: 2).
50 µg PARS were labeled with 10 mM QM-precursor 1c overnight at
rt. The protein was precipitated by TCA precipitation as described in
section 5.3.2. The pellet was taken up in 50 µL 6 M urea in PBS and incu-
bated with 6 µL of 100 mM DTT for 10 min. Then 6 µL of iodoacetamide
(7.4 mg in 200 µL PBS) wre added for 10 min. The sample was diluted
with 90 µL of PBS and digested overnight with 15 µL trypsin at 37 ◦C.
The sample was stored at -20 ◦C until LC-MS/MS measurements which
were conducted as described in section 5.3.2. Protein identification was
performed with MASCOT MS/MS ion search (Matrixscience) against the
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SwissProt-database. Search parameters: taxonomy: proteobacteria, in-
strument: ESI-TRAP, 2 missed cleavage sites, variable modifications: oxi-
dation (M), carbamidomethyl (C), labeling with probe 1c, peptide toler-
ance: 1000 ppm, MS/MS tolerance: 800 mmu, peptide charge: +1,+2,+3
monoisotopic, significance threshold (p<): 0.05, automatic scoring. Pro-
teins were annotated with the in-house program QuPE
[126]
(FDR thresh-
old: 0.05, minimal number of hits: 2).
3.6.4 Biochemical Evaluation of Cyclic Sulfamates
IC50 Inhibition Studies
KARS, PARS, ARSA, ARSB and STS were inhibited by 500 µM and 5 mM
concentrations of CySAs 2a and 40 as well as LiSA 41. Residual activities
of KARS, PARS, ARSA and ARSB were assessed using the pseudosub-
strate 4-MUS at their respective optimum pH values and buffer condi-
tions (KARS: 0.1 M Tris pH 7.0, PARS: 0.1 M Tris pH 8.5, ARSA, ARSB:
0.5 M NaAcOH pH 5.5). It was safeguarded before that 4-MU fluores-
cence behaved linear to its concentration under these conditions.
4-MUS was tested for substrate inhibition and consequently all four
enzymes were assayed with a pseudosubstrate concentration of 5 mM to
avoid any interference with sulfatase activity. The preincubations of in-
hibitors and sulfatases were done in a volume of 20 µL for 60 min and the
inhibitions were stopped by addition of 80 µL of 6.25 mM 4-MUS. Initial
rates of 4-MUS conversion were monitored immediately at an excitation
wavelength of 335 nm and an emission wavelength of 460 nm. The slopes
were converted to activity percent in comparison to uninhibited sulfatase
control.
STS inhibition was measured by E. Ennemann (BCI, Bielefeld Univer-
sity) following the protocol described above for QM precursor probes.
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PARS Active Site Labeling
100 µg purified PARS were inhibited with 20 mM LiSA 41 or 20 mM CySA
2a in a total volume of 50 µL for 60 min at rt with or without the addition
of 20 mM NaCNBH3. For the four inhibited samples no residual activi-
ty was detected when comparing to the uninhibited controls. All three
samples were then treated with 20 mM NaCNBH3 in a total volume of
62 µL for 2 h at 37 ◦C. The samples were precipitated using TCA precip-
itation as described in section 5.3.2. The protein pellets were taken up in
50 µL 50 mM NaAcOH, 150 mM NaCl, 1 % (w/v) SDS, pH 4.0. Protein
concentrations of the samples were evaluated via absorption at 280 nm
using a nanodrop and about 5 µg of protein was used for aldehyde label-
ing of all samples. 0.2 mM fluorescein-5-thiosemicarbazide or 30 eq. of
Alexa Fluor R© 488 hydroxylamine were added to the protein samples and
incubated overnight at rt in the dark.
LC-MS/MS analysis was conducted with approximately 10 µg of the
samples. They were digested with 5 µL of trypsin overnight at 37 ◦C and
stored at -20 ◦C until LC-MS/MS measurement as conducted by Dr. S.R.
Hanson (TSRI, La Jolla).
Biotin-Labeling
10 µg PARS were labeled for 60 min with 20 mM of the biotinylated probe
2d with and without preinhibition by 20 mM CySA 2a or 5 mM LiSA
41 in a total volume of 15 µL. Residual activities were checked before
preinhibited samples were biotin-labeled. The protein was precipitated
with TCA as described in section 5.3.2, and the pellets were taken up in
10 µL 1 % (w/v) SDS at 60 ◦C for 5 min. The resuspended protein was
diluted by a factor of 5 in PBS buffer pH 7.2 and allowed to bind to 25 µL
streptavidin beads for 2 h. The beads were washed 20 µL 3×with 500 µL
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of 0.2 % (w/v) SDS in PBS buffer pH 7.2 and 20 µL 3×with 500 µL PBS pH
7.2. The samples were submitted to 1D-SDS-GE and western blot analysis
by Dr. S.R. Hanson (TSRI, La Jolla).
70 µL STS-overexpressing HT1080 cell lysate as supplied by E. Enne-
mann (BCI, Bielefeld University) were labeled with CySA-biotin 2d using
the same protocol. Labeled samples were enriched using 20 µL magnetic
streptavidin beads. The samples were washed 3 × with MMP buffer, di-
vided in two and each was separated on a 15 % SDS-GE. One gel was sil-
ver stained, the other gel was used for western blotting with streptavidin-
HRP conjugate as described in section 5.3.1. The gel was stripped and
developed again with an αHis antibody as the primary antibody and
αmouse-HRP conjugate as the second antibody by E. Ennemann (BCI,
Bielefeld University).
Fluorescence-Labeling
50 µg of KARS-enriched E. coli lysate were incubated with 1.5 mM probe
2e for 60 min at rt in the dark. The sample was then submitted to 2D-GE
as described in section 5.3.1.
20 µL STS-overexpressing cell lysate (34 µg total protein) as supplied
by E. Ennemann (BCI, Bielefeld University) were labeled with 0, 0.1, 0.5
and 1 mM CySA-alkyne 2b. Another 20 µL of cell lysate were preincu-
bated with 10 mM CySA 2a before labeling with 5 mM 2b as the nega-
tive control. All incubations were conducted for 60 min at 37 ◦C. Sub-
sequently, 1 mM TBTA in DMSO, 1 mM sodium ascorbate and 1 mM 37
were added to the samples and they were mixed. After addition of 1 mM
CuSO4 the reaction was mixed again and then allowed to proceed for
60 min in the dark. The protein was precipitated by acetone precipitation
as described in section 5.3.2 and the protein pellets were taken up in 10 µL
of water and 5 µL of 3× SDS sample buffer and submitted to 1D-SDS-GE.
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of Arabidopsis thaliana MMPs
Matrix metalloproteases are zinc-containing endopeptidases that reside
in the extracellular matrix either as soluble, transmembrane or membrane-
associated proteins.
[10]
Their activity is tightly regulated and misregula-
tions have been linked to various pathological conditions from periodon-
tal inflammation
[129]
over rheumatoid arthritis
[130]
to metastasis, angio-
genesis and other cancer-related processes.
[131]
4.1 Introduction to Matrix Metalloproteases
The Merops database classifies all MMPs in clan MA, family M10. They
are found in bacteria, archaea, fungi, plants, animals and viruses.
[132]
There are 23 genes encoding for human matrix metalloproteases, and all
hMMPs are expressed with a signal peptide for extracellular localization
(pre-domain, Figure 4.1). Most hMMPs are secreted as soluble enzymes
into the ECM
[133]
but there are also five transmembrane (TM) metallopro-
teases referred to as membrane-type hMMPs
[133,134]
as well as two glyco-
sylphosphoinositol (GPI) anchored hMMPs.
[135]
Figure 4.1: Domain structures of MMPs.
All hMMPs contain a pro-domain
that comprises the cysteine switch,
a conserved sequence important
for enzyme latency through ex-
clusion of the catalytically active
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water molecule from the active site.
[136]
The catalytic domain with the
conserved HEXGHXXGXXH-sequence is responsible for zinc ion coordina-
tion. In addition, all except for two hMMPs contain various C-terminal
domains whose functions are not yet fully understood but most probably
involve interaction with their substrates.
[133]
Human MMPs have important functions in tissue remodeling and their
activity is tightly regulated at multiple levels including transcription, ac- MMP
activitiytivation through propeptide cleavage, inactivation by extracellular in-
hibitors and location inside and outside of the cell.
[133]
MMP activation
is post-translationally regulated by inter- and intra-proteolytical removal
of the pro-domain. Thereby, the conserved cysteine residue that coordi-
nates the active site zinc ion is displaced and a water molecule can enter
instead.
[137]
Once activated, MMPs are controlled by four classes of in-
hibitors found in the ECM: tissue inhibitors of metalloproteases (TIMPs),
a peptide generated by proteolytic cleavage of the procollagen C-protei-
nase enhancer, the membrane-anchored reversion-inducing cysteine-rich
protein with Kazal motifs (RECK) and α2-macroglobulin.
[133]
An imba-
lance of this post-translational regulation is connected to various patho-
logical conditions.
[129–131,138]
Classically, hMMPs are described as tissue remodeling enzymes with
a role in protein homeostasis of the extracellular space. They are the MMP
functionsonly enzymes that can degrade triple-helical collagen as well as many
other proteinaceous ECM components (e.g. aggrecan, casein, elastin, fi-
bronectin, gelatin, laminin, nidogen, perlecan, proteoglycan link protein,
serpins, tenascin, versican and vitronectin). However, more and more
non-matrix constituting substrates have been identified. Some of them
trigger the release of growth factors (e.g. tumor necrosis factor α, fi-
broblast growth factor 1, insulin-like growth factor 1 and transforming
growth factor β) by either cleavage of growth-factor binding proteins or
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matrix proteins to which the growth-factor binding proteins attach.
[133]
MMPs are also responsible for shedding of membrane-bound proteins
(L-selectin,
[139]
soluble Fas ligand
[140]
) for growth-factor release. In addi-
tion to the activation, MMPs also proteolytically inactivate growth factors
and cytokines both directly (e.g. chemokine connective tissue activating
peptide III, monocyte chemoattractant protein, stromal cell-derived fac-
tor 1
[141]
) and indirectly through shedding of receptors (fibroblast growth
factor receptor
[142]
). MMPs are also important for the immune system
since they activate part of the innate immune response (defensins, by
cleavage of their prodomain
[143]
) and cleave immunoglobulin G
[144]
to
prevent the complement cascade.
Apart from vertebrates, MMPs have been found in various organisms:
Caenorhabditis elegans, [145] Drosophila, [146] sea urchin, [147] hydra, [148] Volvox
carteri, [149] and Chlamydomonas reinhardtii. [150] In these cases, MMPs were
found to play diverse roles in development and tissue remodeling as was
expected from their homology to hMMPs.
Plant MMPs have been described for soybean,
[151,152] Arabidopsis thali-
ana, [21] Cucumis sativus, [153] Medicago trancatula, [154] pine, [155] Nicotiana
tabacum, [156] and N. benthamiana. [157] Plant MMPs are encoded by intron-plant
MMPs less genes and, like most of their human homologs, consist of a signal
peptide, a pro-domain, a catalytic protease domain carrying the zinc-
binding motif and often a C-terminal transmembrane domain. They play
versatile biological roles in growth and development
[153–155,158]
as well as
in pathogen and symbiont infections.
[156,157,159]
Transcript levels of MMP-
encoding genes in soybean, tobacco and N. benthamiana are strongly in-
duced during infection with pathogenic bacteria,
[156,157,159]
and silencing
NMMP1 in N. benthamiana enhances susceptibility to infections by Pseu-
domonas syringae pv. tabaci. [157] Furthermore, MtMMPL1 from M. trun-
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catula is induced early during nodulation with symbiotic bacteria, and
silencing of this gene disturbs the nodulation process.
[154]
The Arabidopsis thaliana genome encodes for At1–5-MMPs [21] which
all display a high homology to hMMP-7. At1-, At2-, At3-, and At5-MMPs At-MMPs
carry a C-terminal transmembrane domain and At3-MMP carries an ad-
ditional putative GPI anchor motif.
[21]
Similar to the activation of hu-
man MMPs,
[137]
incubation with an organomercury compound like para-
aminophenylmercuric acetate with At1-MMP leads to the formation of
an active truncated protein of 25 kDa.
[21]
It can be assumed that At2–5-
MMPs also require processing before they gain activity. Once activated,
animal MMPs are regulated by endogenous proteinaceous inhibitors,
[137]
but no functional inhibitor homologs have been identified in plants yet.
Plant MMPs are interesting research subjects involved in diverse biolo-
gical processes. However, their post-translational regulation hampers a
prediction of their activity based on transcript or protein levels. A direct
readout of At-MMP activity in complex proteomes by affinity-based pro-
tein labeling would therefore represent a valuable tool to provide func-
tional information.
4.1.1 Affinity-Based Studies of Matrix Metalloproteases
There are only very few mechanism-based inhibitors described for MMPs.
The derivatization of such an electrophile- and mechanism-based cova-
lent inhibitor of MMPs
[160]
into ABPP probes is compromised by either
weak potency
[161]
or restricted target selectivity.
[162]
Because the catalytic
mechanism of metalloproteases does not involve a covalent intermediate
with its substrate,
[10]
metalloprotease probes are based on reversible in-
hibitors, equipped with a photoreactive group.
[12–17]
Photoaffinity probes
that target the active site of an enzyme display the availability of the ac-
tive site, which is a hallmark for enzyme activity. Proteins that have af-
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finity to the reversible inhibitor are subsequently covalently attached via
photo-activation by irradiation with light.
The principle of using a photoreactive probe in combination with strep-
tavidin-based pull-down and subsequent LC-MS/MS-based identifica-
tion of the extracted proteins is called capture compound mass spectro-
metry (CCMS).
[163]
In contrast to classical activity-based proteomics, CC-
MS potentially addresses all proteins interacting reversibly with a small
molecule including inhibitors, substrates or substrate analogs and drugs.
Figure 4.2: Marimastat 42 and batimastat 43 are ex-
amples for hydroxamate inhibitors of a broad range of
hMMPs.
Hydroxamates are a well-studied
group of reversible inhibitors suit-
able for metalloprotease probes.
They are bidendate chelators that
bind the zinc ion in the active site
and are potent broad-spectrum in-
hibitors of MMPs. Marimastat 42
and batimastat 43 (Figure 4.2) are
two important examples of this
compound class.
[164]
Most hydroxamate metalloprotease probes exhibit
structural similarities to these two inhibitors.
[12–16]
All previously pub-
lished probes can be further divided into three groups.
The first group contains marimastat-like probes which all carry a hy-
droxyl group adjacent to the hydroxamate functionality as well as an
iso-propyl side chain next to it. In comparison to marimastat 42, other
residues addressing the metalloproteases’ S2’ pocket are introduced as a
panel of amino acids to generate probe libraries. The methyl group of
the C-terminal amide is substituted by a linker conjugated to the reporter
group or a bioorthogonal attachment site (i.e. an alkyne functionality).
The photoreactive group can either be part of this linker-reporter sub-
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stituent or address the S2’ pocket instead of the tert-leucin of marimastat
42.
[12,13]
The second group comprising most metalloprotease probes are hy-
droxamate derivatives of succinic acid. The hydroxyl group of marima-
stat 42 is substituted by a hydrogen atom. The S1’ pocket of the target
enzyme is addressed by various amino acid side chains
[13,14]
or the pho-
toreactive group
[15]
similar to the P2’ site (photoreactive group
[13,14]
or
amino acid side chain
[13]
). The C-terminal methyl group of marimastat
42 is substituted by a linker bearing the reporter group.
[13–15]
The third and smallest group of hydroxamate probes are peptides with
a hydroxamate functionality at their C-terminus. The reporter group
and different photocrosslinkers are attached via linker moieties to the N-
terminus of the peptide.
[16]
Another very different set of hMMP probes are phosphinic peptides
exhibiting Ki values in the picomolar range.
[17]
Interestingly, these mo-
lecules are most potent when used without irradiation as pure affinity
purification tools.
[166]
There are also other non-covalent approaches tar-
geting metalloproteases with hydroxamates. These probes lack the pho-
toreactive group and are attached to a solid support for inhibitor affinity
chromatography.
[19,20,23,165]
However, so far only one study succeeded in
the detection of native hMMPs from synovial fluid
[20]
and no attempts
have been made to extend this approach to the investigation of MMPs
outside of human samples.
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4.2 Objectives
To investigate MMPs in plants, a photoaffinity probe based on the MMP
inhibitor marimastat 42 should be applied in this study. Such an ap-
proach seemed reasonable since plant MMPs are sensitive towards hydro-
xamate inhibitors: At1-MMP
[21]
and Cs1-MMP from cucumber
[153]
are
efficiently inhibited by batimastat which shares a similar inhibition pro-
file with marimastat.
[164]
Since first experiments to characterize endoge-
nous proteins using an affinity-based approach with A. thaliana leaf ex-
tracts were not effective, At1–5-MMPs should be overexpressed in planta.
Also, previous efforts to express these extracellular plant proteins in E.
coli did not succeed due to the formation of inclusion bodies. [167] At-MMP
overexpressing leaf lysates should be investigated by covalent labeling
with a marimastat-bearing probe. The subsequent analysis of the cap-
tured proteins could be done by biotin-based enrichment and LC-MS/MS
analysis.
4.3 Development of Covalently-Binding
Marimastat Probes
For probe synthesis, a previously described marimastat-linker conjugate
[18]
was coupled to a biotinylated linker construct containing an azidotetraflu-
orobenzoyl group as the photoreactive moiety to yield probe 3. Another
marimastat-benzophenone conjugate
[24]
was biotinylated to give probe
44. These coupling steps were conducted by Dr. C. Dalhoff (caprotec
bioanalytics GmbH, Berlin).
These probes differ from previously described hydroxamate-based pro-
bes
[12–16]
as the majority of published probes are peptidomimetics of suc-
cinyl hydroxamate.
[13–15]
The hydroxyl group adjacent to the hydroxa-
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mate is missing and various amino acids to target the S2’ pocket of the
enzyme are employed (compare to Figure 4.3). Some of the hydroxylated
hydroxamate-based probes contain their photoreactive group or different
amino acid side chain residues to target the S2’ pocket. Even though these
probes are similar to our probes 3 and 44, the original marimastat moiety
with the tert-butyl group in the S2’ position has never been used to cova-
lently label MMPs before.
Figure 4.3: Structure of the Marimastat-based probes 3 and 44 which were used for
labeling of Arabidopsis thaliana MMPs.
The position
[15]
and nature
[16]
of the photoreactive group of MMP tar-
geting probes seem to be more important for labeling efficiency of pho-
toactivatable probes than their inhibitory moiety. We therefore incor-
porated an azidotetrafluorobenzoyl moiety into probe 3 and benzophe-
none into probe 44 (Figure 4.3) in comparison to the previously used
benzophenone
[12,13,16]
and trifluoromethyldiazirin groups.
[14–16]
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The IC50-value for the inhibition of recombinant hMMP-2 by probe 3 was
determined to be 4.7± 0.9 nM. If the sample was irradiated during inhi-
bition, the value slightly increased to 11.1±0.6. An IC50-value can still
be determined with covalent photoinduced crosslinking since this bond
probably still allows for diffusion of the marimastat moiety out of the ac-
tive site. The photoreactive group cannot bind to the catalytic site as this
is blocked by marimastat. Such an inhibition mode is comparable to pro-
MMP where the Cystein-switch is covalently attached to the protein and
closes the active site via a non-covalent interaction.
[136]
The measured
values are comparable to marimastat 42 itself with an experimental IC50-
value of 3.2±1.0 nM [23] and a reported value of 6 nM for MMP-2. [164]
The affinity of probe 3 is relatively high, since other previously reported
metalloprotease probes had IC50-values in the range of low nM to high
µM.
[12–16]
In addition to inhibition, the labeling properties of probe 3 were eval-
uated with recombinant hMMP-9. The labeled protein was pulled down
with streptavidin beads and subsequently trypsinated. LC-MS/MS anal-
ysis of the captured protein yields a sequence coverage for hMMP-9 of
17 % with 13 unique peptides, 16 unique spectra and 17 total spectra
(green peptides in Figure 4.4). The specificity of labeling was monitored
by preincubation with marimastat prior to addition of probe 3. Only one
peptide was identified in this sample (green and underlined peptide in
Figure 4.4). The general applicability of probe 3 for affinity-based inves-
tigation of MMPs was thereby successfully demonstrated and the probe
was used for the labeling of overexpressed Arabidopsis thaliana MMPs.
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Figure 4.4: Sequence coverage of probe 3 labeling of human recombinant MMP-9
is 17 % as indicated by the labeled peptide fragments. Propeptide, cysteine
switch, HEXGHXXGXXH domain, the signal peptide is underlined. The peptide
identified in the control sample is green and underlined.
4.4 Transient At-MMP Expression
Full-length At1–5-MMPs were supposed to be expressed by cloning the
respective genes into a binary vector behind the CaMV 35S promoter and
transformation into Agrobacterium tumefaciens. Transient overexpression
can then be achieved by Agrobacterium infiltration of Nicotiana benthami-
ana leaves which results in nearly native At-MMPs with a plant pro-
tein background: a well-suited model to optimize labeling with probe
3. The workflow of At-MMP overexpression was amplification of Ara-
bidopsis thaliana cDNA by PCR (4.4.1); cloning into the replication plasmid
pFK26
[168]
for simple and fast amplification of the DNA by E. coli and
cloning into the binary vector pTP5
[168]
which is pertinent for replication
as well as protein expression. Another amplification step of the plasmid
in E. coli is followed by the transformation of Agrobacterium tumefaciens
(4.4.2) which enables the bacteria to induce protein expression in plants
via agroinfiltration
[168]
(4.4.3).
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Polymerase Chain Reaction
For expression of all five predicted At-MMPs, primers were designed by
Dr. Kaschani (MPI for Plant Breeding Research, Cologne). PCR was done
using cDNA of Arabidopsis thaliana col-0 which was prepared by Dr. Som-
mer (MPI for Plant Breeding Research, Cologne). The HA-tag which later
allows a selective detection of the expressed At-MMPs via western blot-
ting was C-terminally added by add-on-primers.
Figure 4.5: Agarose gel of crude PCR
products (left) and the subsequent purifi-
cation (right). 1: At2-; 2: At3-; 3: At4-;
4: At1-; 5: At5-MMP.
As depicted in Figure 4.5 it appears as if all
five genes were successfully amplified from
cDNA. The biproducts which are clearly vis-
ible in the agarose gel of the crude PCR pro-
ducts (left panel, Figure 4.5) could be removed
by purification using a DNA purification kit
(right panel, Figure 4.5). No optimization of
PCR was needed at this point since all constructs were amplified to yield
products of the expected respective DNA lengths. PCR was not antici-
pated to work without optimization in light of precedent experiments on
the expression of At-MMPs in E. coli which required extensive adjustment
of PCR parameters.
[167]
Transformation
Figure 4.6: Agarose gel of
purified digests. 1: At2-; 2:
At3-; 3: At4-; 4: At1-; 5:
At5-MMP; 6 and 7: pFK26.
To incorporate these amplified DNA fragments into the
replication plasmid pFK26,
[168]
the plasmid and the At-
MMP-encoding DNA needed to be cut by restriction en-
zymes that produce sticky ends. The enzymes NCoI/PstI
or XhoI/PstI (see section 4.6.2) were used for DNA restric-
tion, and the agarose gel in Figure 4.6 shows the purified
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digests. Ligation of plasmid and inserts was done using the T4-DNA lig-
ase to yield the five plasmids ready for amplification in E. coli.
Figure 4.7: Agarose gels of colony PCR. Purple frames indicate
the clones selected for nucleotide sequencing.
Transformation of E. coli
was achieved by electropo-
ration
[170]
and subsequent
plating of the bacteria on
ampicillin LB-plates for se-
lection. Successful incor-
poration of the At-MMP
DNA fragments was veri-
fied by colony PCR of 16
clones for each construct
(Figure 4.7). Except for
At3-MMP, enough positive
clones were selected and the framed ones were purified and submitted
to nucleotide sequencing. For At3-MMP, further 64 clones were picked
which resulted in four positive clones. All of them were purified and
submitted to sequencing.
The sequencing results were satisfying for At1-, At2-, At4- and At5-
MMPs (see Figure 4.8). All sequenced clones contained several mutations
on the gene level which were only partially silent and therefore cause
mutations within the protein sequences. The clones with the least amount
of protein mutations were used for further studies.
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Figure 4.8: Protein sequences of the four At-MMPs which were selected for further
experiments. The predicted
[21]
signal peptide is underlined, mutated amino acid
residues, cysteine switch, plant specific conserved motif, HEXXH domain,
transmembrane domain followed by the HA-tag (YPYDVPDYA).
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Two At1-clones were used for all further experiments since both con-
tained mutations that might influence their activity: S2A and N30D for
At1a- and S2A, F15L and V267A for At1b-MMP. The sequence of At2-
MMP bore only one mutation (T148A). The selected mutant of At4-MMP
only had mutations within the predicted
[21]
cleavable signal peptide: H2G
and L22F. The selected clone of At5-MMP contained four substitutions:
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R2G, E55K, M222T and S281P. For At3-MMP none of the picked clones
included the desired sequence. Even though various efforts were made
to optimize PCR for this At-MMP including new primer design, differ-
ent polymerase enzymes, change of PCR buffer and variation of the PCR
program, it was not possible to amplify this gene from cDNA. Due to lack
of time, PCR could also not be optimized for the other At-MMPs until
non-mutated genes were obtained. All attempts to apply a proof-reading
DNA polymerase failed.
These selected inserts were shuttled into the binary vector pTP5 using
EcoRI and HindIII as restriction enzymes. This vector comprises three an-
tibiotic resistance sites (gentamycin, kanamycin and rifampicilin) for se-
lection. The plasmids were first inserted into E. coli for amplification rea-
sons, then purified and transformed into Agrobacterium tumefaciens also
by means of electroporation. All steps worked well as can be derived
from the colony PCR products of the Agrobacterium transformation (Fig-
ure 4.9). The clones with the strongest signal were chosen for protein
expression as indicated by the purple frames.
Figure 4.9: Agarose gel of the colony PCR of transformed Agrobacterium tumefa-
ciens. The framed clones were later used for agroinfiltration.
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Agroinfiltration and At-MMP Expression
Agroinfiltration with coexpression of the silencing inhibitor p19 was done
as previously described.
[176]
The cloned MMPs were transiently overex-
pressed as C-terminally HA-tagged proteins for detection and purifica-
tion purpose.
Figure 4.10: Phenotypes of the five expressed
At-MMPs and p19 as a control 3–6 days after
agroinfiltration.
Four-week-old Nicotiana plants were in-
filtrated with the respective Agrobacteria
clones and harvested after three to six
days post agroinfiltration since Agrobac-
terium tumefaciens-mediated protein ex-
pression usually reaches the highest level
after two to three days.
[177]
Phenotypes of
the five At-MMPs and p19 as a control
were documented by photography of the
leaves after harvest (Figure 4.10). In con-
trast to the p19-expressing leaves, it be-
comes evident that all At-MMPs caused se-
vere phenotypes with the strongest cha-
racteristics for At1b- and At2-MMP. Tis-
sue death was probably related to elevated
levels of the respective MMP activity in-
duced by endogenous activation of the
pro-At-MMPs. The level of protease activi-
ty could also have been influenced by the
amount of protein expressed in each leaf
which varies from plant to plant and leaf
to leaf. Even though all plants were grown under the same conditions,
natural variation might still occur.
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Figure 4.11: Expression analysis of harvested
At-MMP-expressing leaves by western blotting.
Left panel with αHA-biotin and streptavidin-
HRP detection: 1: p19 control; 2: At4-MMP
after 3 d, 3: At4-MMP after 4 d, 4: At4-MMP
after 5 d, 5: At4-MMP after 6 d. Right panel
with αHA-HRP detection: 6: At2-, 7: At4-, 8:
At1a-, 9: At1b-, 10: At5-MMP, 11: p19 con-
trol.
At4-MMP expressing leaves were ana-
lyzed 3–6 days after agroinfiltration by
western blotting with αHA-biotin and
streptavidin-HRP (Figure 4.11, left panel).
The time-dependent evaluation shows
that expression reaches the highest level
three days after infiltration (Figure 4.11,
lane 2–5). By comparing the phenotype of
At4-MMP expressing leaves (Figure 4.10)
with the blotting results, it becomes clear
that leaf tissue damage corresponds with
a decrease of protein yield. These results
led to the harvest of leaves used for label-
ing studies 3–4 days after agroinfiltration.
The αHA-biotin blot exhibits a high amount of background detection.
This could be either caused by endogenously biotinylated proteins which
bind to streptavidin-HRP, non-specific binding of αHA-biotin or a com-
bination of both. Since cross-detection averts a clear evaluation of HA-
tagged At-MMPs, the more expensive but much more specific αHA-HRP
conjugate (Figure 4.11, right panel) was used for all further western blots.
TheαHA-biotin in combination with streptavidin-HRP only detected At4-
MMP. In contrast to that, the more specific antibody-HRP conjugate was
able to visualize At2- with a mass of about 60 kDa, At4- with a mass
of about 42 kDa and At5-MMP with a mass of about 55 kDa (Figure
4.11, lanes 6, 7 and 10). These protein sizes are consistent with the ex-
pected molecular masses of glycosylated proteases with aglycon masses
of 41, 35 and 39 kDa for the HA-tagged proteins without the presumably
cleavable
[21]
signal peptide. The expression of both mutated At1-MMP
proteins was not visible by western blotting even though the respective
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overexpressing leaves exhibited strong phenotypes (compare Figure 4.10).
This might be due to a lower solubility of At1-MMPs in the extraction
buffer compared to At2-, At4- and At5-MMPs. Another explanation could
be the C-terminal cleavage of the HA-tag which would completely avert
binding of α-HA conjugates.
4.5 Photochemical Affinity-Based Labeling of
At-MMPs
To investigate whether plant MMPs are susceptible to the marimastat-
based tool 3, extracts of leaves transiently expressing At-MMPs were in-
cubated and UV-crosslinked with probe 3. Preincubation with an excess
of marimastat 42 prior to labeling with probe 3 was used as an indica-
tor for labeling specificity. Extracts of leaves overexpressing the silencing
inhibitor p19 served as a control for the detection of endogenously bi-
otinylated proteins.
Figure 4.12: Western blot analysis of At4- and
At5-MMP labeling by probe 3. a) streptavidin-
HRP after labeling; b) αHA-HRP before labeling;
c) αHA-HRP after labeling. 1: p19 with mari-
mastat, 2: p19, 3: At4-MMP with marimastat,
4: At4-MMP, 5: At5-MMP with marimastat, 6:
At5-MMP.
Streptavidin-based detection of labeled
proteins revealed specific, marimastat-
sensitive signals of 25 kDa in At4-
MMP and 35 kDa for At5-MMP leave
lysates (Figure 4.12a, lanes 3/4 and 5/6).
These signals did not appear in extracts
of leaves not overexpressing At-MMPs
(Figure 4.12a, lanes 1/2). A 30 kDa sig-
nal appears in all lanes and represents an
endogenously biotinylated protein (Fig-
ure 4.12a, lanes 1–6).
The αHA-HRP western blot proves
that there were full-length At4- and At5-
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MMPs in the leave lysates before labeling (Figure 4.12b). However, after
labeling these signals have disappeared in all samples (Figure 4.12c). A
possible explanation could be a complete extraction by probe 3 but since
the bands also disappeared in the samples which were pretreated with
marimastat as a specificity control protein degradation most probably oc-
curred.
The molecular mass of the labeled proteins is about 15 kDa lower
than that of the full-length pro-At-MMP detected before labeling (com-
pare Figure 4.12a, lanes 4 and 6 with 4.12b, lanes 3 and 5). The reduced
sizes of labeled At-MMPs compared to the full-length protein masses is
in agreement with the fact that plant MMPs are active as processed 20–
36 kDa isoforms. At1-MMP, for example, is active as a 27 kDa protein,
[21]
soybean MMP (SMEP1) was isolated as a 19 kDa active protease,
[151]
cu-
cumber MMP is active as 22 and 18 kDa isoforms,
[153]
and tobacco MMP
is active as 36 and 22 kDa isoforms.
[171]
Similarly, the 62 kDa human MMP-2 produces a 43 kDa isoform that
lacks part of the protease domain C-terminal to the HEXGH domain
[172]
and the 82 kDa human MMP-9 produces a 35 kDa mature proteases.
[173]
The mechanisms of post-translational regulation in MMPs are not com-
pletely understood yet and the physiological functions of the various ac-
tive isoforms are still under discussion. C-terminal truncation may alter
substrate specificity as the C-terminal domain is important for substrate
binding.
[10,172,173]
These aspects should be further investigated by time-
dependent labeling of At-MMP lysates and addition of various protease
inhibitors to determine when cleavage occurs as well as the class of pro-
tease which is responsible for MMP truncation.
To unambiguously confirm the identity of the probe 3-labeled proteins,
we enriched the labeled proteins on magnetic streptavidin beads. The
samples were digested on-bead with trypsin and eluted peptides were
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analyzed by LC-MS/MS (Figure 4.13). At4-MMP was identified from
the At4-MMP-expressing sample, with 21 spectral counts covering 48 %
of the protein sequence (Figure 4.13). One peptide of the endogenous
MMP from N. benthamiana (NMMP) [157] was also identified in this sample
(Figure 4.13). From the At2-MMP containing samples, three At2-MMP
peptides were identified with moderate scores (Figure 4.13) even though
the streptavidin blot did not show biotinylated proteins apart from the
30 kDa protein abundant in all samples (data not shown). Two peptides
were identified from the At5-MMP sample which cover 8 % of the At5-
MMP sequence (Fig. 4.13).
Figure 4.13: Protein sequences of the four At-MMPs which were identified in LC-
MS/MS analyses of probe 3-labeled leaf lysates. The predicted
[21]
signal peptide is
underlined, identified peptides, peptides identified in marimastat control.
.
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Importantly, no peptides were found for At2-MMP, At5-MMP as well as
NMMP and only two peptide spectral counts for At4-MMP if the samples
were preincubated with an excess of marimastat 42 (Figure 4.13). These
findings confirm that labeling is specific since it can be efficiently com-
peted by addition of marimastat 42; the original hMMP inhibitor. It is in-
teresting to note that of all five Arabidopsis MMPs, only At4-MMP lacks a
C-terminal transmembrane domain. This property correlates with the ob-
servation that At4-MMP causes the strongest signal in the western blots
of leaf lysates (Figure 4.12c) as well as in the labeling experiments (Figure
4.12a). These observations indicate that further adjustments of the pro-
tein extraction procedure from the overexpressing leaves are needed to
detect the other MMPs more efficiently.
The peptide coverage indicates that the labeled At4-MMP retained
most of its prodomain. The presence of a prodomain in a labeled MMP
implies that it was not inhibiting protease activity efficiently during the
labeling procedure. Otherwise, the active site zinc would have been co-
ordinated by the cysteine switch motif of the prodomain so that it could
not have been available to bind the hydroxamate moiety in probe 3. The
presence of a prodomain in active MMPs is not unprecedented. The active
isoform of human MMP-9 also contains part of the prodomain with the
cysteine switch.
[174]
Furthermore, inhibition of human MMPs by TIMP-1
traps the protease in a prodomain-containing isoform.
[175]
Therefore, the
detection of part of the prodomain does not exclude MMP activity.
The same labeling workflow as described above was applied to the At-
MMP-expressing leave lysates using probe 44. However, no At-MMP la-
beling was detected by streptavidin blotting or LC-MS/MS analysis (data
not shown). The inferior labeling performance of the benzophenone-
bearing probe 44 is supported by the literature. In a comparative study
of the labeling efficiencies of metalloprotease probes with benzophenone
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and trifluoromethyldiazirine as reactive groups, no labeling of spiked
metalloprotease in crude lysates was observed for a benzophenone probe
in contrast to a clear signal for a diazirine probe.
[16]
4.6 Conclusion
Transient expression of At-MMPs was successfully induced to generate
enriched leaf lysates which served as model proteomes to transfer affinity-
based proteomics for the first time to plant proteins. Probe 3 was devel-
oped in cooperation with caprotec bioanalytics GmbH, Berlin. It specifi-
cally labels plant MMPs from Arabidopsis thaliana and most probably also
Nicotiana benthamiana. It could be shown that trifluoromethyldiazirine 3
is a more efficient photocrosslinker than benzophenone 44 for this ap-
plication which is in good correlation with previous reports.
[16]
Labeling
of At-MMPs was optimized using At-MMP overexpressing Nicotiana leaf
lysates. These protocols can now be used to detect endogenous MMPs in
different proteomes and thereby derive evidence concerning their role in
plant physiology.
4.7 Experimental Section
4.7.1 Probe Evaluation
IC50 Determination of Human MMP-2
Inhibition of 2 nM recombinant hMMP-2 by concentrations in the range
0.2–2000 nM of of probe 3 was assessed using 5.5 µM of the fluorogenic
MMP-2/MMP-7 substrate in a final volume of 100 µL. Liberated fluo-
rophore was excited at 330 nm and fluorescence was detected at 405 nm.
Percent residual MMP activity was determined based on measured fluo-
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rescence for a given inhibitor concentration in comparison to uninhibited
enzyme. The measurements were done in triplicates which were repeated
twice. GraphPad Prism 4.0 was used to evaluate the data and calculate
IC50 values.
Labeling of Human MMP-9
100 ng hMMP-9 in MMP buffer were incubated with 1 µM probe 3 in the
presence or absence of 500 µM marimastat in a final volume of 100 µL
for 5 min on ice. The samples were UV-irradiated for 4 min at 2 ◦C in a
200 µL-PCR tube strip using the caproBox (caprotec bioanalytics GmbH,
Berlin). 25 µL 5 × wash buffer was added to each of the samples. After
homogenization, 20 µL 10 mg/mL streptavidin-coated magnetic beads
were added and the samples were incubated for 3 h at 4 ◦C keeping
the beads in suspension by rotation. The beads were collected using the
caproMag and the supernatant was discarded. The beads were washed
with 200 µL for each washing step: 6 × with 1 × wash buffer (diluted
from the 5 × wash buffer), once with water, 6 × with 80 % (v/v) ACN
and once with water. On-bead tryptic digestion was performed overnight
at rt under vigorous shaking (>2000 rpm) using 0.5 µg trypsin in 10 µL
50 mM ammonium bicarbonate. The beads were magnetically collected
at the side of the tube inner wall, the supernatant containing the pep-
tides was transferred into a new tube, dried in a vacuum centrifuge, and
stored at -20 ◦C. The peptides were analyzed by Dr. O. Gräbner (capro-
tec bioanalytics GmbH, Berlin) via LC-MS/MS using the LTQ Orbitrap
XL mass spectrometer (Thermo Fisher Scientific, Germany). The MS/MS
data were analyzed by SEQUEST and X!Tandem.
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4.7.2 Expression of At-MMPs
Polymerase Chain Reaction
PCR was conducted as described in section 5.3.4. For DNA amplification
of At-MMP genes total cDNA (extracted from Arabidopsis thaliana col-0 by
Dr. Sommer at MPI, Cologne) and the following primers were used:
At1-MMP:
forward primer: 5’-GATCCATGGCTCGTAATTTAATCTATAGAAGAAACAGAGCTC-3’
reverse primer: 5’-GCATCTGCAGCTAAGCGTAATCTGGAACATCGTATGGGTATAGGA-
AAAGAATCAAACCAACAACCAAC-3’
At2-MMP:
forward primer: 5’-ATGGTCTCGAGCGTTTTCGGGTTTTTATCGCTTTTC-3’
reverse primer: 5’-GCATCTGCAGCTAAGCGTAATCTGGAACATCGTATGGGTACGGTA-
AGAACCACAAGACCAATC-3’
At3-MMP:
forward primer: 5’-GATCCATGGTGAGGATTTGTGTTTTCATGGTT-3’
reverse primer: 5’-GCATCTGCAGCTAAGCGTAATCTGGAACATCGTATGGGTACACTA-
AATACAAAAATAATCCAAATATAATCCA-3’
At4-MMP:
forward primer: 5’-GATCCATGGGGCATCATCATCATCATCCATGCAATC-3’
reverse primer:5’-GCATCTGCAGCTAAGCGTAATCTGGAACATCGTATGGGTACCAATT-
AAGAAAACAGAGAGCGATAACA-3’
At5-MMP:
forward primer: 5’-GATCCATGGGAACACTTCTTCTAACGATTTTGATCTTCTTC-3’
reverse primer: 5’-GCATCTGCAGCTAAGCGTAATCTGGAACATCGTATGGGTAAACAGA-
AATCAAGAATATACACGTGGCA-3’
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Transformation
Restriction enzyme digestion, ligation and transfection was conducted as
described in section 5.3.5. with the following enzymes:
At2-MMP: XhoI and PstI
At1-MMP, At3-MMP, At4-MMP, At5-MMP: NcoI and PstI
The ligation was done with the digested cDNA from PCR and the
pFK26
[168]
plasmid. Transfection of the pFK26 vectors with inserts into E.
coli cells was done by electroporation and positive clones were screened
by colony PCR (5.3.4) with the plasmid specific primer r112
[168]
and the
respective gene specific primer. The cells were grown in presence of
Ampicillin.
pFK26 plasmids containing the inserts were digested and ligated into
the binary vector pTP5
[168]
plasmid using the quick digestion and ligation
method (5.3.5). E. coli transfection was done by electorporation and the
bacteria were grown in presence of 50 µg/mL kanamycin. The plasmids
were purified and used for Agrobacterium tumefaciens transformation via
electroporation as described in section 5.3.5. A. tumefaciens were grown
in presence of kanamycin, rifampicilin and gentamycin.
Agroinfiltration of Nicotiana benthamiana leaves
A. tumefaciens were cultivated as described in section 5.3.3 and infiltrated
as detailed in section 5.3.6. After harvest, the leaves were photographed,
frozen in liquid nitrogen and stored at -80 ◦C until use. N. benthamiana leaf
lysates were prepared by grinding leaves in millipore water. The extract
was cleared by centrifugation at 13,000 rpm using a bench centrifuge and
diluted with water to give a protein concentration of 1 mg/mL. Expres-
sion was monitored by western blotting as described in section 5.3.1 using
either αHA-biotin and streptavidin-HRP or αHA-HRP for detection.
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4.7.3 Labeling of At-MMPs with Probe 3
For Streptavidin Blotting Conducted by Dr. F. Kaschani
N. benthamiana leaf lysates were prepared by grinding leaves in 0.4 M bo-
rate buffer, pH 7.6.
[178]
The extract was cleared by centrifugation and di-
luted with cross-linking buffer to give a protein concentration of 1 mg/mL.
100 µL of the samples were transferred to a 96-well plate and pretreated
with marimastat 42 in DMSO (500 µM final concentration) or DMSO for
10 min. After addition of probe 3 (1 µM final concentration), crosslinking
was started by placing a hand-held UV lamp (exposing with wavelengths
of 275 and 375 nm) on top of the 96-well plate. The samples were irradi-
ated for 20–30 min on ice. The reaction was stopped by addition of 25 µL
4 × sample buffer and heating samples to 90 ◦C for 5 min. 10–15 µL
sample was separated by 1D-SDS-GE and blotted onto PVDF membrane.
Protein blots were incubated with mouse α-HA antibody and α-mouse-
HRP or streptavidin-HRP in 4 % BSA in TBS-T. Membranes were washed
extensively in between antibodies and prior to detection of signals with
ECL.
For Enrichment on Streptavidin Beads
For enrichment of proteins labeled with probe 3, 100 µL At-MMP-ex-
pressing Nicotiana benthamiana leaf lysates in MMP buffer were treated
as described above for hMMP-9. The MS/MS data were analyzed by
Dr. O. Gräbner (caprotec bioanalytics GmbH, Berlin) using SEQUEST
and X!Tandem searching a combined database containing tobacco and N.
benthamiana proteins which was supplemented with the HA-tagged Ara-
bidopsis MMPs.
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Table 4.1: Results of LC-MS/MS analysis after labeling At2-, At4- and At5-
MMP expressing leaf lysates with probe 3.
Peptide Sequence Sequest
XCorr Score
At2-MMP
(K)NPLTEEVK(S) 2.36
(R)DLTYAFDPK(N) 1.93
(R)YTLFPGEPR(W) 1.91
At4-MMP
(R)LHLDKAETWAVDFDEEK(S) 6.47
(R)HLQQYGYLPQNKESDDVSFEQALVR(Y) 5.73
(R)LHLDKAETWAVDFDEEK(S) 5.58
(R)DVPLKLTYAFSQENLTPYLAPTDIR(R) 4.96
(R)DVPLKLTYAFSQENLTPYLAPTDIRR(V) 4.55
(K)NLGLPITGKPDSDTLSQILLPR(C) 4.45
(K)LTYAFSQENLTPYLAPTDIRR(V) 4.27
(R)HLQQYGYLPQNK(E) 4.23
(K)LTYAFSQENLTPYLAPTDIR(R) 4.14
(K)IGFFNGDHGDGEPFDGVLGVLAHTFSPENGR(L) 3.90
(K)ESDDVSFEQALVR(Y) 3.69
(K)NLGLPITGKPDSDTLSQILLPR(C) 3.41
(R)HLQQYGYLPQNK(E) 3.13
(K)SSVAVDLESVAVHEIGHVLGLGHSSVK(D) 2.57
(K)ESDDVSFEQALVR(Y) 2.47
(K)NLGLPITGKPDSDTLSQILLPR(C) 2.38
(K)DAAMYPTLKPR(S) 2.26
(K)DAAmYPTLKPR(S) 2.05
(K)DAAmYPTLKPR(S) 2.03
(K)TAPFHTGK(K) 1.34
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(Y)AFSQENLTPYLAPTDIR(R)
NMMP
(R)DLTYAFLPQNGLTDNIK(S) 2.86
At4-MMP neg. control
(K)ESDDVSFEQALVR(Y) 3.64
(K)NLGLPITGKPDSDTLSQILLPR(C) 2.50
At5-MMP
(K)DDIEGIQHLYGGNPnGDGGGSKPSR(E) 5.26
(R)SESILR(A) 1.33
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5.1 Synthesis: Analytical Methods, Solvents, and
Reagents
Chromatography
Column chromatography was conducted as flash chromatography with
silica gel (0.040-0.063 mm, Macherey-Nagel) under slight application of
pressure. Thin layer chromatography was performed with Silica gel 60
F254, non-modified on aluminum plates (Merck). Detection was achieved
by UV light (254 nm, Desaga MinUVIS), with 5 % (w/v) ninhydrine in
EtOH (dipping, heating), and with 5 % (w/v) (NH4)6Mo7O24·4 H2O, 0.2 %
(w/v) Ce(SO4)2, 5 % (w/v) H2SO4 in water (dipping, heating). Analytical
RP-HPLC: Pump: Thermo Separation Products P4000, detector: Thermo
Separation Products UV 6000 LP (detection at λ = 220 nm/254 nm), con-
troller: Thermo Separation Products SN 4000, column: Phenomenex Jupi-
ter 4 µm Proteo 90 C18, 4.6·250 mm), eluent A: 5 % (v/v) H2O, 95 % (v/v)
ACN, 0.1 % (v/v) TFA, eluent B: 95 % (v/v) H2O, 5 % (v/v) ACN, 0.1 %
(v/v) TFA, flow: 1 mL/min, method:
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Table 5.1: Method for analytical HPLC.
Time [min] Eluent A [%] Eluent B [%]
0 0 100
3 0 100
35 100 0
40 100 0
45 0 100
Preparative RP-HPLC: Pump: Thermo Separation Products P4000, de-
tector: Thermo Separation Products UV1000 (detection at λ = 220 nm),
controller: Thermo Separation Products SN4000, column: Phenomenex
Jupiter 10 µm Proteo 90 C12, 21.2·250 mm), eluent A: 5 % (v/v) H2O,
95 % (v/v) ACN, 0.1 % (v/v) TFA, eluent B: 95 % (v/v) H2O, 5 % (v/v)
ACN, 0.1 % (v/v) TFA, flow: 10 mL/min, method:
Table 5.2: Method for preparative HPLC.
Time [min] Eluent A [%] Eluent B [%]
0 0 100
3 0 100
35 100 0
40 100 0
45 0 100
Spectroscopy
NMR spectra were recorded on a Bruker DRX-500 (1H-NMR: 500.1 MHz,
13C-NMR: 125.8 MHz). Deuterated chloroform with TMS as internal stan-
dard was mostly used as solvent. Other deuterated solvents were refer-
enced to the residual solvent peak.
[169]
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Mass Spectrometry
MALDI-ToF: PerSeptive Biosystems Voyager-DE, LSI nitrogen laser: λ =
337 nm, 1.20 m flight tube, 20 kV acceleration voltage, delay time: 90–
150 ms, grid voltage: 93–95 %, guide wire voltage: 0.05 %, scans: 25–
100, low mass gate: 300 Da, calibration: instrument default calibration,
software: Voyager Instrument Control Panel Version 5.10, Data Explorer
Version 4.0.0.0 (Applied Biosystems), matrix: 2,5-dihydroxybenzoic acid.
ESI-MS: Bruker Daltonik Esquire 3000, ion source: standard ESI/APCI
source, sample introduction: direct infusion by syringe pump, nebulizer
and dry gas: nitrogen, Bruker Nitrogen Generator NGM 11, cooling and
collision gas: helium.
ESI-FT-ICR: Bruker Daltonik APEX III, magnet: 7.0 T 160 mm bore super-
conducting magnet, infinity cell, ion source: nano-ESI, nebulizer and dry
gas: nitrogen, Bruker Nitrogen Generator NGM 11, cooling and collision
gas: helium.
Solvents
All solvents were purchased in p.a. quality. Solvents of lower quality
were purified by distillation. Anhydrous solvents were obtained as fol-
lows: Et2O: Na/Ph2CO, DCM: CaH2, DMF: ninhydrine. Water for HPLC
and all aqueous solutions was obtained from a Millipore MilliQ ultrapure
water system (>18 MΩ·cm−1). Acetonitrile for HPLC was purchased in
Lichrosolv quality from Merck.
Reagents and Chemicals
Chemicals were purchased from Acros, Merck, Sigma-Aldrich, VWR, Alfa
Aesar and Fluorochem. All materials were used without further purifi-
cation except for the following: sulfuryl chloride: freshly distilled, zinc
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dust: stirred in 1 M HCl, filtered, and washed with water, methanol, and
DCM.
5.2 Biochemical Material
Material and Laboratory Equipment
2D-SDS-PAGE SE Ruby, Höfer
96-well plate for Bradford as-
say and sulfatase inhibition
studies
Tissue Culture Plate, Sarstedt
96-well plate for MMP acti-
vity assays
Bicro Well, NUNC
Bench centrifuge miniSpin, Eppendorf
caproBox caprotec bioanalytics GmbH, Berlin
caproMag caprotec bioanalytics GmbH, Berlin
CCD-camera LAS-3000, Fujifilm
Centrifuge 5810 R, with swing-out rotor A-4-62
and fixed-angle rotor F-34-6-38, Ep-
pendorf
DNA purification kit plasmid purification kit, Qiagen
Electroporator Electroporator 2510, Eppendorf
Fluorogenic MMP-2/MMP-7
substrate
Calbiochem
Immobiline DryStrips pH 3–
10NL, 18 cm
GE Healthcare
Incubator Hood: TH-15, Shaker: KS-15, Edmund
Bühler GmbH
In-gel fluorescence detection λex = 460 nm, detection filter: FL-Y515,
LAS-3000, Fujifilm
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Isoelectric focusing EttanTMIPGphor II Isoelectric Focu-
sing System, GE Healthcare
LC-MS/MS nano-column 15 cm × 75 µm, Acclaim PepMapTM
C18, 100 , Dionex
LC-MS/MS pump 1D-NanoLC Eksigent Technologies
LC-MS/MS spectrometer LCQ Deca, Thermo Fisher Scientific
LC-MS/MS nanospray nee-
dle
uncoated, 15 µm tip, New Objective
Magnetic Streptavidin beads Dynabeads MyOne Streptavidin C1,
Invitrogen Dynal
Microplate reader infinite M200, software: i-Control 1.4,
Tecan
p19-expressing A. tumefaciens
culture
supplied by Dr. R.A.L. van der Hoorn,
MPI, Cologne
pH Electrode Inlab 420 pH electrode, Mettler Toledo
pH-Meter MP220 pH Meter, Mettler Toledo
Pipettes 10, 20, 100, 200, 1000, 5000, Eppendorf
Plasmid purification kit Nucleospin, Macherey & Nagel
Plasmids pFK26 and pTP5 were supplied by Dr.
R.A.L. van der Hoorn, MPI, Cologne
Power supply EPS 601, Amersham Biosciences
Primer Operon
PVDF membrane BioTraceTM PVDF Membrane, Pall
Life Sciences
SDS-PAGE, small gel cham-
ber
Xcell sure lock, Novex Mini-Cell, In-
vitrogen
SDS-PAGE, big gel chamber SE Ruby, Höfer
Sonifier Model 450, Branson
Spectrometer Heλios γ, Spectronic Unicam
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Thermomixer Thermomixer compact, Eppendorf
Water filtration system Milli-Q, Millipore
Western blotting chamber custom-made, Bielefeld University
Whatman filter paper GE Healthcare
Buffers and Solutions
Buffers were solved and diluted using water obtained from a Millipore
MilliQ ultrapure water system. pH adjustment was achieved with 1 M
HCl and NaOH solutions. All buffers were filtered (pore size 0.22 µm)
and degassed. All chemicals were used in p.a. or BioChemika quality.
3 × sample buffer 200 mM Tris·HCl pH 6.8, 25 % (w/v)
glycerine, 6 % (w/v) SDS, 0.06 %
(w/v) bromophenol blue, 5 % (v/v) β-
mercaptoethanol
4 % stacking gel buffer (for 2
big gels)
4.81 mL water, 2.10 mL stacking buffer,
83.5 µL 10 % (w/v) SDS in wa-
ter, 0.84 mL 40 % acrylamide/N,N’-
methylenebisacrylamide 29:1, 8.35 µL
TEMED, 0.50 mL 1.5 % (w/v) APS in
water
5 × wash buffer 250 mM Tris HCl, pH 7.5, 5 mM
EDTA, 5 M NaCl, 42.5 µM octyl-β-D-
glucopyranoside
10 × Ammonium buffer 10 × Ammonium buffer 15 mM
MgCl2, Amplicon
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10 % resolving gel buffer (for
2 big gels)
15.38 mL water, 9.37 mL resolving gel
buffer, 375 µL 10 % (w/v) SDS in wa-
ter, 9.37 mL 40 % acrylamide/N,N’-
methylenebisacrylamide 29:1, 18.7 µL
TEMED, 3.00 mL 1.5 % (w/v) APS in
water
15 % resolving gel buffer (for
2 big gels)
12.38 mL water, 11.25 mL resolving gel
buffer, 450 µL 10 % (w/v) SDS in wa-
ter, 16.88 mL 40 % acrylamide/N,N’-
methylenebisacrylamide 29:1, 22.5 µL
TEMED, 3.60 mL 1.5 % (w/v) APS in
water
Agarose sealing solution 190 mM glycine, 25 mM Tris·HCl,
0.1 % (w/v) SDS, 0.0002 % (w/v) bro-
mophenol blue
Blotting buffer 100 mL methanol, 100 mL 10 × SDS
electrophoresis buffer, 800 mL water
Bradford assay buffer Coomassie Protein Assay Reagent,
Thermo Scientific
Colloidal coomassie stain 0.02 % Coomassie BB-G250, 5 % (w/v)
AlSO4·14 H2O, 10 % (v/v) EtOH, 2 %
(v/v) o-phosporic acid
Coomassie stain Imperial Protein Stain, Thermo Scien-
tific
Cross-linking buffer 25 mM Tris pH 7.5, 60 µM ZnCl2
Developing solution 15 g Na2CO3, 5 mL sensitizing so-
lution, 125 µL 37 % formaldehyde,
250 mL water
EcoRI Buffer EcoRI Buffer, New England Biolabs
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Enhanced Chemilumines-
cence
Luminol reagent 1, Luminol reagent 2,
Roth
Equilibration buffer I 6 M urea, 75 mM Tris·HCl pH 8.8,
29.3 % (v/v) glycerine, 2 % (w/v) SDS,
0.002 % (v/v) bromophenol blue, 1 %
(w/v) DTT
Equilibration buffer II 6 M urea, 75 mM Tris·HCl pH 8.8,
29.3 % (v/v) glycerine, 2 % (w/v) SDS,
0.002 % (v/v) bromophenol blue, 2.5 %
(w/v) iodoacetamide
Fixing solution 500 mL ethanol, 100 mL acetic acid,
400 mL water, 500 µL 37 % formalde-
hyde
Infiltration buffer 10 mM MES, pH 5, 10 mM MgCl2,
1 mM acetosyringone
LB medium 1 % (w/v) tryptone, 1 % (w/v) NaCl,
0.5 % (w/v) yeast extract, pH 7.0
MMP buffer 50 mM Tris·HCl pH 7.5, 0.2 M NaCl,
5 mM CaCl2, 0.02 % (w/v) Brij 35
MMP-2/MMP-7 Substrate,
Fluorogenic
Calbiochem
Oil PlusOne Dry Strip Cover
Fluid
GE Healthcare
PBS buffer 10 mM Na2HPO4·H2O, 1.8 mM
KH2PO4, 2.7 mM KCl, 140 mM NaCl,
pH 7.2
Rehydration buffer 0.5 % (v/v) IPG-buffer pH 3–10 in
DeStreakTM rehydration solution, GE
Healthcare
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Resolving gel buffer 1.5 M Tris·HCl, pH 8.8
SDS electrophoresis buffer 190 mM glycine, 25 mM Tris·HCl,
0.1 % (w/v) SDS
Sensitizing solution 100 mg Na2S2O3·5 H2O, 500 mL water
Stacking gel buffer 0.5 M Tris·HCl, pH 6.8
Staining solution 400 mg AgNO3, 150 µL 37 % formalde-
hyde, 200 mL water
Stop solution 60 mL acetic acid, 220 mL ethanol,
220 mL water
T4 DNA Ligase buffer Promega
TAE buffer 40 mM Tris·HCl, 40 mM acetic acid,
1 mM EDTA, pH 8.0
TBS buffer 50 mM Tris·HCl pH 7.5, 150 mM NaCl,
0.02 % (w/v) Brij 35
TBS-T buffer 0.1 % (v/v) Tween-20 in TBS buffer
Proteins
αHA proteins Monoclonal Anti-HA-Biotin (Mouse,
Clone HA-7, 1:2500), Sigma-Aldrich;
Anti-HA-HRP (3F10, 1:2000), Roche;
α-HA antibody (Mouse, 8:10000),
Sigma
α-mouse-HRP α-Mouse-HRP (Rabbit, 6:10000),
Pierce
ARSA, ARSB Supplied as purified enzyme by Prof.
T. Dierks, BCI, Bielefeld University
ARSG Supplied as purified enzyme by Dr.
M.-A. Frese, BCI, Bielefeld University
BSA PAA Laboratories GmbH
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hMMP-2 Proenzyme, Human, Recombinant,
CHO Cells, Calbiochem
hMMP-2 Proenzyme, Human, Rheumatoid,
Synovial, Fibroblast 1:1-complex with
TIMP-2, Calbiochem
hMMP-9 Proenzyme, Human, Recombinant,
CHO Cells, Calbiochem
Ligase T4 DNA Ligase, Promega
KARS Supplied as purified enzyme by M.
Schröder, OCIII, Bielefeld University
PARS Supplied as purified enzyme by Dr. S.
R. Hanson, TSRI, La Jolla
Prepurified KARS Expressed in E. coli and purified by ion
exchange chromatography, Biochem-
istry Practical Course 2008, Bielefeld
University, Germany
[83]
Protein Marker Prestained Protein Marker, Broad
Range, New England Biolabs
Protein Marker SeeBluer Plus, Invitrogen
Proteinase inhibitor cocktail proteinase inhibitor cocktail 1:100,
Sigma
Restriction endonucleases XhoI, PstI, NcoI, HindIII, EcoRI, New
England Biolabs
Streptavidin-HRP Ultrasensitive streptavidin-HRP
(1:5000), Sigma-Aldrich
Taq DNA polymerase Taq polymerase, Amplicon
Trypsin sequencing grade, Roche; Seq. Grade
Modified Trypsin, Porcine, Promega
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5.3 General Biochemical Methods
5.3.1 Electrophoresis
Agarose Gel Electrophoresis
Gels were prepared by dissolving 1 % (w/v) agarose in TEA buffer. The
agarose was melted in a microwave, ethidium bromide was added to a fi-
nal concentration of 0.5 µg/mL, and the solution was poured into a sealed
gel casting platform. The DNA samples to be resolved were mixed with
respective volumes of DNA loading buffer. The electrophoresis was per-
formed in a gel chamber filled with TEA at a voltage of 120 V for 20 min.
SDS-GE
[179]
Protein samples were separated according to protein size by SDS-GE un-
der denaturing conditions. Small gels (8× 7 cm) were cast into disposable
cassettes. For big gels (15× 13 cm) glass plates with spacers were used as
described in the manual. Resolving gels were allowed to polymerize for
1–3 h before the stacking gels were cast on top.
Samples for SDS-GE were mixed with corresponding volumes of 3 ×
sample buffer and denatured for 5 min at 95 ◦C, briefly centrifuged and
loaded on the gel. Electrophoresis of small gels was performed at con-
stant voltage of 125 V per gel for 60 min in SDS electrophoresis buffer.
Big gels were run at 100 V per gel for 15 min and 200 V per gel for 3 h.
Proteins were then either blotted, stained with Coomassie or colloidal
Coomassie stain. Briefly, gels were washed 3 × 5 min with water and
stained overnight. Destaining was achieved by washing with water. For
dilute samples, MALDI-ToF compatible silver staining was used: Gels
were fixed for at least 60 min in fixing solution and then washed twice for
25 min each in ethanol/water = 1:1. The gels were incubated for 1 min in
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sensitizing solution and then washed 3× 20 s in water. Staining was done
for 20 min in staining solution followed by washing with water (3× 20 s).
The gel was transferred to a new container and then developed in devel-
oping solution for about 3–5 min, until the desired staining was almost
achieved. The gel was quickly washed with one change of water and
then stop solution was added for at least 10 min. Afterwards the gel was
washed 3 × 10 min with water.
2D-GE
Protein samples were diluted with 310-330 µL rehydration buffer to give
a final volume of 340 µL and submitted to isoelectric focusing on Immo-
biline dry strips as described in the manual. The following program was
used for focusing: 1. Step: 10 V, 1 h; 2. Step: 30 V, 12 h; 3. Step: 500 V, 1 h;
4. Gradient: 1000 V, 8 h; 5. Gradient: 8000 V, 3 h; 6. Step: 8000 V, 2 h; 7.
Step: 100 V, until further use of strips.
Subsequently, the strips were equilibrated for 15 min each in equilibra-
tion buffers I and II before being placed on a 10 % SDS gel. The strips were
sealed with agarose sealing solution and electrophoresis was conducted
as described above for big gels.
Western Blotting
Following 1D- or 2D-GE, proteins were transferred to PVDF membranes
for protein detection via specific interactions of an antibody or streptavidin-
biotin binding. The gel, the membrane and two sheets of Whatman pa-
per were equilibrated in blotting buffer, and piled on an electrophoresis
chamber for semi-dry transfer. Proteins were blotted at a constant cur-
rent of 1 mA/cm2 for 66 min. After blotting the membrane was blocked
in 4 % (w/v) BSA in TBS-T for 5 min at rt on a rotator. Streptavidin-HRP,
αHA-Biotin or αHA-HRP was added and incubated for 60 min at rt or
132
5.3 General Biochemical Methods
overnight at 4 ◦C. The membrane was washed 5 × 5 min at rt with TBS-
T. Then, either streptavidin-HRP was applied, incubated and washed as
described, or, protein signals were immediately detected by ECL. Equal
volumes of each luminol reagent were premixed and applied to the mem-
brane. The signals were visualized using a CCD-camera.
5.3.2 Protein Analysis
Determination of Protein Concentration
Protein concentrations were measured using Bradford assay buffer as de-
scribed in the supplied manual. Briefly, 5 µL of each protein sample
were mixed with 150 µL of assay buffer and absorbance was detected at
595 nm. Values were normalized using a buffer blank and protein concen-
trations were calculated from a reference curve using BSA as a standard.
All assays were performed in triplicates.
Protein Precipitation
Acetone precipitation: The protein sample was resuspended in four vol-
umes of ice-cold acetone and incubated for 60 min at -20 ◦C. The pre-
cipitated proteins were pelleted by centrifugation at 4 ◦C for 30 min at
10,000 g. The supernatant was discarded and the pellet was allowed to
dry under a stream of N2.
Trichloroacetic acid (TCA) precipitation: One volume of 100 % (w/v)
TCA was added to four volumes of protein sample and incubated for
10 min at 4 ◦C. The sample was centrifuged at 13,000 rpm in a bench
centrifuge for 5 min. The supernatant was removed and the pellet was
washed three times with 200 µL of ice-cold acetone. The protein pellet
was dried under a stream of N2.
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In-Gel Tryptic Digestion
Protein bands or spots were cut out from coomassie stained gels and
divided into 1 mm3 pieces. The gel slabs were washed with 250 µL of
ACN/H2O = 1:1 (5 min), ACN/50 mM NH4HCO3 = 1:1 (30 min), ACN/
10 mM NH4HCO3 = 1:1 (2 h) and then dried under a stream of N2. 15 µL
10 mM NH4HCO3 and 1 µL trypsin were added and incubated for 2 h at
37 ◦C. Another 20 µL of 10 mM NH4HCO3 were added to prevent drying
of the gel pieces. The digests were incubated overnight at 37 ◦C. The sam-
ples were removed from the gel pieces, lyophilized, and stored at -20 ◦C
until LC-MS/MS measurement.
Identification of Proteins by LC-MS/MS
All measurements of sulfatase samples were conducted by B. Müller (Tech-
nical Faculty, Bielefeld University). The lyophilized samples were dis-
solved in 10 µL 5 % ACN/0.1 % TFA, and submitted to nano-LC-MS/MS
analysis using a nano-column coupled to the mass spectrometer via a
fused silica capillary (50 µm) and a nanospray needle. Eluents: A =
95 % (v/v) H2O, 5 % (v/v) ACN, 0.1 % (v/v) FA; B = 20 % (v/v) H2O,
80 % (v/v) ACN, 0.1 % (v/v) FA. Method: flow rate 200 nL/min, gra-
dient (A:B): 0–5 min: 98:2, 5–40 min: 98:2–50:50. Ionization and sample
uptake by the mass spectrometer were conducted with a spray/needle
voltage of 1.2 kV and a capillary voltage of 30 V at 170 ◦C. Relevant pre-
cursor ions were selected automatically for MS/MS-acquisition using the
X-calibur softwareTM (Thermo Fisher Scientific). Peptide fragmentation
was initiated by collision energy (30 % CE, activation time: 30 ms) in
the ion-trap MS. All MS/MS-spectra were converted to mzXML-files us-
ing ReAdW 4.0.2 (Seattle Proteome Center). Protein identification was
performed with MASCOT MS/MS ion search (Matrixscience) against the
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SwissProt-database. Search parameters: taxonomy: proteobacteria, in-
strument: ESI-TRAP, 2 missed cleavage sites, variable modifications: ox-
idation (M), carbamidomethyl (C), labeling with probe 1c, peptide toler-
ance: 1000 ppm, MS/MS tolerance: 800 mmu, peptide charge: +1,+2,+3
monoisotopic, significance threshold (p<): 0.05, automatic scoring. Pro-
teins were annotated with the in-house program QuPE
[126]
(FDR thresh-
old: 0.05, minimal number of hits: 2).
5.3.3 Bacteria Cultivation
E.coli: LB medium containing 10 µg/mL ampicilin or 50 µg/mL kanamy-
cin was agitated at 37 ◦C.
Agrobacterium tumefaciens: LB medium containing 50 µg/mL rifampicilin,
50 µg/mL kanamycin and 10 µg/mL gentamycin was agitated at 28 ◦C.
Glycerol stocks
Glycerol stocks of bacteria were prepared from 500 µL of a fresh overnight
culture which was mixed with 500 µL of 50 % (v/v) glycerol. The glycerol
cultures were stored at -80 ◦C until use.
5.3.4 Polymerase Chain Reaction
All PCR samples were set up in a volume of 70 µL, containing 53 µL
millipore water, 2 µL cDNA, 7.5 µL 10 × Ammonium buffer, 1 µL each
of 10 µM forward and reverse primers, 1.5 µL 10 mM dNTPs and 1 µL
Taq DNA polymerase. Cycling parameters were 2 min at 94 ◦C, 20 s at
94 ◦C, 25 s at 56 ◦C, 2 min at 72 ◦C, with 26 cycles and a final step of
5 min at 72 ◦C. The resulting DNA fragments were resolved by prepara-
tive agarose gel electrophoresis and purified using the DNA purification
kit.
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For this purpose, cDNA bands were quickly excised from the gel under
UV irradiation. The gel slabs were weighed and the weight was multi-
plied by the percentage of the original agarose gel: for 100 mg·% 300 µL
buffer QG were added and incubated at 37 ◦C for 15 min to solubilize
the cDNA. The resulting solution was applied to the purification column,
washed with 500 µL QG buffer, 750 µL PE+EtOH buffer and then dried by
centrifugation (11,000 rpm for 3 min). The DNA was eluted by incubation
with 30 µL EB for 2 min at rt and subsequent centrifugation at 13,000 rpm
for 3 min.
For colony PCR, eight colonies of each agar plate were picked with
a sterile yellow pipet tip which was then put into a 96-well plate well
containing 50 µL sterile water. PCR samples of a total volume of 25 µL
contained 15.2 µL millipore water, 5 µL of the picked colony in water,
2.5 µL 10 × Ammonium buffer, 0.75 µL of each primer, 0.5 µL 10 mM
dNTPs and 0.3 µL Taq DNA polymerase. Cycling parameters were 2 min
at 94 ◦C, 20 s at 94 ◦C, 25 s at 56 ◦C, 2 min at 72 ◦C, with 26 cycles and a
final step of 5 min at 72 ◦C.
5.3.5 Transformation of Bacteria
Restriction Enzyme Digestion and Ligation
15 µL of the purified cDNA (insert) and 5 µL of the purified plasmids
were digested in a total volume of 60.6 µL containing 6 µL 10 × NE3
buffer, 0.5 µL of each restriction enzyme and 0.6 µL BSA 100 × purified.
The digestion proceeded for 2 h at 37 ◦C without agitation. The digests
were then purified using the DNA purification kits. The samples were
first diluted with a fivefold volume of PBI buffer and then applied to the
purification columns. The columns were washed twice with 750 µL PE
buffer and dried by centrifugation (13,000 rpm, 2 min). The digests were
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eluted after incubation with 30 µL EB for 2 min at rt and subsequent cen-
trifugation at 13,000 rpm for 2 min.
Ligation was done in a total volume of 30 µL with 4 µL of the digested
plasmid, 3 µL of the digested insert and 1 µL ligase in T4 DNA Ligase
buffer. After 60 min of incubation 1 µL of ligase was added and the liga-
tion was allowed to proceed for another 60 min. The DNA was then pre-
cipitated by first adding 3 µL of 3 M NaOAc, pH 5.2 followed by 30 µL
of isopropanol, a short incubation on ice and centrifugation at 13,000 rpm
and 4 ◦C for 30 min. The pellet was carefully washed once with 70 %
(v/v) EtOH and then taken up in 10 µL millipore water.
Quick Digestion and Ligation Method
Plasmids were digested in a total volume of 100 µL. 5 µL of the plasmid
with insert and 5 µL of the new plasmid were mixed with 10 µL of EcoRI
Buffer, 1.5 µL HindIII, 1.5 µL EcoRI and 77 µL water. The samples were
incubated for 2 h at 37 ◦C and then for 15 min at 72 ◦C. The DNA was
precipitated by addition of 5 µL 3 M NaOAc and 100 µL isopropanol and
incubation for 15 min on ice. The DNA was pelleted by centrifugation at
13,000 rpm for 30 min and 4 ◦C. The pellet was washed once with 50 µL
70 % (v/v) EtOH and centrifuged again at 13,000 rpm for 10 min and 4 ◦C.
The pellet was taken up in the ligase mix (3 µL T4 DNA Ligase buffer,
1 µL Ligase and 26 µL water) and incubated for 2 h at rt. The DNA was
precipitated again as described after the digestion step. The DNA was
taken up in 10 µL water.
Electroporation of Bacteria
Competent E. coli (DH10B, Invitrogen) or A. tumefaciens (GV3101) bacte-
ria were transformed with purified plasmid DNA using electroporation
(1800 V).
[170]
For each transformation reaction 50 µL cells were thawed
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on ice, mixed with 3 µL of the purified plasmids and incubated on ice
for 1 min. The cells were then transferred to a sterile UV cuvette and in-
serted into the electroporator. Immediately after electroporation, 1 mL of
LB medium was added and the bacteria were incubated for 1 h at 37 ◦C
before spreading them on agar plates containing the respective antibi-
otics. The success of transformation was monitored by colony PCR and
agarose gel electrophoresis. The three most promising clones were se-
lected for plasmid purification and nucleotide sequencing.
Plasmid Purification
For plasmid purification with the plasmid purification kit, an overnight
culture was pelleted by centrifugation at 1670 g at 4 ◦C for 20 min. The
pellet was taken up in 250 µL A1 Buffer and transferred into an Eppendorf
tube. 250 µL of A2 Buffer were added, the mixture was inverted well
and incubated for 4 min at rt. 300 µL A3 Buffer were added, the tubes
were inverted and centrifuged for 15 min at 13,000 rpm. The supernatant
was applied to the column and spun down for 1 min at 11,000 rpm. The
column was subsequently washed with 500 µL AW and 600 µL A4 Buffer
with centrifugation for 1 min at 11,000 rpm each. The column was dried
by centrifugation for 2 min at 11,000 rpm. The plasmids were eluted by
incubation with 50 µL AE Buffer for 2 min at rt and then spun down for
1 min at 11,000 rpm. 20 µL of the eluate was submitted to sequencing.
5.3.6 Transient Expression of Proteins in N. benthamiana by
A. tumefaciens Infiltration
Overnight A. tumefaciens cultures were centrifuged at 1500 g for 20 min
and 4 ◦C. The bacteria were resuspended in infiltration buffer and incu-
bated for 2 h at rt. The OD600 was adjusted to 2 and the cultures ex-
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pressing At-MMPs were mixed in a 1:1 ratio (v/v) with p19-expressing A.
tumefaciens. N. benthamiana leaves of four week-old plants were infiltrated
with the bacteria suspension and allowed to grow (14 h light, 10 h dark)
for 3–6 days. Only p19-expressing cultures were used for control plants.
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Activity- and affinity-based proteomics methods as applied in this work
offer unprecedented opportunities to characterize enzymes using their
respective activity or affinity profiles (Figures 6.1 and 6.2).
Figure 6.1: The activity-based proteo-
mics workflow as applied to the investi-
gation of sulfatases. Samples were la-
beled and then either analyzed via 2D-
GE tryptic digestion and MS-based fin-
gerprint analysis or enriched, tryptically
digested and identified via MS.
Figure 6.2: Affinity-based proteomics
approach as applied to leaf lysates
expressing At-MMPs. Samples were la-
beled, irradiated and then investigated by
streptavidin blotting as well as enriched,
tryptically digested, and the bound
proteins were identified via LC-MS/MS.
The output of these techniques can be manifold: novel enzymes are iden-
tified from crude lysates or changes in the activity of individual enzymes
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and enzyme families can be monitored. Thereby, the physiological roles
that enzymes play in cells and/or organisms are elucidated. In this work,
two enzyme classes were investigated: sulfatases by activity-based pro-
teomics and matrix metalloproteases by affinity-based proteomics.
Since sulfatases are key players in diseases such as cancer and inflam-
mation as well as hereditary disorders, activity-based proteomics pro-
vides important methods to attain information about their catalytic in- Sulfatases
tegrity in these processes. Sulfatase-directed QM traps were examined
based on masked monofluoromethylphenyl sulfates as quinone methide
precursors for sulfatases. The sulfatase-directed probe 1a
[40,107]
was found
to have mechanism-dependent irreversible inactivation properties against
aryl sulfatases in comparison to previously designed difluoromethylphe-
nyls.
[9]
MFPS 1c was active against aryl sulfatases operating at neutral
and basic pH, including bacterial PARS and KARS and human STS; how-
ever, they were not active against the human lysosomal enzyme ARSG
(active under acidic conditions).
Figure 6.3: Structures ofMFPS QM precursor probe 1a with fluorescein as reporter
group and MFPS inhibitor 1c.
Despite good inactivation and reasonable reactivity toward the enzyme
class, 19F-NMR experiments of MFPS 1c with purified PARS and KARS
demonstrated that sulfatase inactivation occurs only after an excess of
QM traps are enzymatically generated. This leads to multiple enzyme
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labeling events as shown by LC-MS/MS analysis of 1c-labeled KARS and
PARS, presumably through non-specific QM capture of the enzymes.
The activity of fluorescent MFPS probe 1a in complex proteomes con-
firmed that the sulfatase-directed QM traps required enzymatic activa-
tion, but lead to non-specific labeling of many different enzyme classes.
Furthermore, QM trapping sites on the bacterial sulfatase PARS are most
probably on solvent exposed regions of the enzyme as investigated by
LC-MS/MS of tryptic digests of 1c-labeled PARS. Unfortunately, such be-
havior does not meet the stringent requirements for activity-based pro-
teomics, which must be able to decisively report on the activity of a spe-
cific enzyme class by turnover-dependent labeling in the context of the
greater proteome.
[33]
Therefore, it can be concluded that quinone methide
probes are not suitable for activity-based proteomics studies of sulfatases,
since selective labeling of their target enzymes is too slow and diffusion
of the activated species takes place.
In search for a different suicide inhibitor which could be incorporated
into the presented modular probe synthesis, alkynylated cyclic sulfamates
2b and 2c as well as azido-reporter groups 37 and 39 were synthesized
and biochemically evaluated.
Figure 6.4: Cyclic sulfamates 2a, b and c and reporter groups 37 and 39.
Apparently, CySAs target and modify the active site FGly residue. This
was shown by labeling PARS with CySA 2a which impairs labeling of the
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aldehyde-targeting fluorescence dye Alexa Fluor R© 488 hydroxylamine.
Even though the CySA labeling mechanism leads to a product robust
enough to be detected after SDS-GE, it escapes a direct characterization
by LC-MS/MS which only shows a decrease of the FGly-bearing PARS
fragment after CySA 2a labeling. First 1D- and 2D-GE labeling studies
are promising to further pursue the investigation of sulfatase activity by
cyclic sulfamates with the molecular tools now in hands.
Fluorescence microscopy could now be employed to visualize sulfa-
tase activity in tissue samples. This might prove a valuable method for
sulfatase deficiency diagnostics in the future. It would also be possible to Matrix metallo-
proteasesscreen cell lysates to identify novel sulfatases.
Figure 6.5: Photoreactive Marimastat-based affinity probe
with biotin as the reporter group.
Matrix metalloproteases are
a newly described family
of plant proteins with in-
teresting physiological roles
in growth and develop-
ment as well as pathogen
defense.
[21,156,158]
Probe 3
which is based on the hu-
man MMP inhibitor mari-
mastat 42 was developed in
cooperation with caprotec bioanalytics GmbH, Berlin and proved to be a
high-affinity photoreactive probe for hMMPs.
To apply this probe to plant MMPs, four Arabidopsis thaliana MMPs
were transiently overexpressed inNicotiana benthamiana leaves via agroin-
filtration. Marimastat-probe 3 was successfully applied to label overex-
pressed At2-, At4- and At5-MMP, and additionally an endogenous Nico-
tiana benthamiana MMP in total leaf extracts by means of streptavidin blot-
ting and LC-MS/MS analysis. This labeling was marimastat-sensitive
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which is a strong indicator for the specificity of binding. Affinity-based
photoreactive capturing was thereby successfully applied to plant sam-
ples for the first time. The labeling of NMMP should be further pursued:
MMPs have only once been identified from an endogenous source before
(synovial fluid of an arthritis patient which contains elevated levels of
active hMMPs).
[20]
Since most At-MMPs are transmembrane proteins, their signals should
be increased by optimizing the protein extraction protocol to enrich for
membrane proteins. Application of the developed probe and the estab-
lished workflow will hopefully contribute to the elucidation of the role
and post-translational regulation of plant MMPs during plant-pathogen
interactions and other biological processes.
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